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Abstract 
 Colorectal carcinoma (CRC) has one of the highest incidences and mortality on the 
modern society, but a growing impact on less developed and economically transitioning nations. 
Prevention, surgery and radio/chemotherapy are the principal approaches to overcome the 
disease. Finding new efficient/specific treatments in CRC, better tolerated by patients is 
mandatory.  
News strategies to be used against colorectal cancer emerged when it was found that 
certain strains of Propionibacterium could protect against CRC. Those bacteria, living in the 
human intestine, produce short-chain fatty acids (SCFAs), namely acetate, butyrate and 
propionate that are able to induce apoptosis specifically on CRC cells. The mechanisms behind 
these occurrences are not fully understood. Ceramide is an important signalling molecule, vital in 
cellular processes and may play a role in regulation of apoptosis in CRC cells. Previous research 
executed by our laboratory showed that acetate-induced apoptosis in CRC cell lines and lysosome 
membrane permeabilization (LMP) with cathepsin D release. The fact that ceramide promotes 
LMP and activates cathepsin D, led us to hypothesize that ceramide might be generated in 
response to acetate and thus mediate apoptosis induced by this lethal stimulus, in CRC cells.  
The main objective of the project was to assess the involvement of ceramide in acetate-
induced apoptosis on CRC derived cell lines (HCT-15 and RKO). In order to reach that goal, cells 
were treated with acetate and/or inhibitors of the ceramide biosynthesis pathways (GW4869, 
fumonisin B1 and myriocin) and cellular viability was analysed by MTT assay.      
 The inhibition of the three major pathways of ceramide generation (de novo, salvage and 
sphingomyelinase pathways) did not change significantly the cellular viability, on both cell lines. 
Indeed the expected increase in cellular viability did not occur when cells were treated with 
acetate and one or more inhibitors of ceramide synthesis pathways. Further studies are 
necessary to confirm the results obtained, namely determining ceramide cellular levels, and the 
activity of enzymes involved in ceramide synthesis treated with acetate and/or ceramide 
inhibitors.  
 Summing up, the results obtained so far suggest that acetate-induced cell death in HCT-
15 and RKO CRC cells might not be mediated by ceramide. 
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Resumo 
O carcinoma colo-rectal (CCR) tem uma das maiores incidências e mortalidade na 
sociedade moderna, mas um impacto crescente em países menos desenvolvidos e em vias de 
desenvolvimento. A prevenção, cirurgia e a rádio/quimioterapia são as principais abordagens 
usadas no combate à doença. É importante encontrar novos tratamentos mais eficazes, 
específicos e melhor suportados pelos pacientes. 
  Novas estratégias para serem usadas contra o CCR surgiram aquando da descoberta de 
que algumas estirpes do género Propionibacterium poderiam fornecer proteção contra o CCR. 
Essas bactérias, que vivem no intestino do Homem, produzem ácidos gordos de cadeia curta, 
como o acetato, o butirato e o propionato, que são capazes de induzir a apoptose específica das 
células do CCR. Os mecanismos que levam a essas ocorrências não estão bem compreendidos. 
A ceramida é uma molécula de sinalização importante e vital em processos celulares, e poderá 
desempenhar um papel na regulação da apoptose em células de CCR. Investigação prévia do 
nosso laboratório, mostrou que o acetato induz apoptose em linhas de CCR, bem como a 
permeabilização da membrana lisossomal (PML) com libertação de catepsina D. O facto de se 
saber que a ceramida promove a PML e activa a catepsina D, levou-nos a colocar a hipótese de 
que a ceramida poderia ser gerada em resposta ao acetato e poderia mediar a apoptose 
induzida por esse estímulo letal, em células do CCR. 
O principal objectivo do projeto foi avaliar o envolvimento da ceramida na apoptose 
induzida pelo acetato, em células do CCR (HCT-15 e RKO). Para atingir essa meta, as células 
foram tratadas com acetato e um ou mais inibidores das vias de síntese da ceramida (GW4869, 
fumonisin B1 e myriocin) e a viabilidade celular foi analisada recorrendo a ensaios de MTT. 
A inibição das três principais vias de produção de ceramida (de novo, selvagem e das 
esfingomielinases) não alterou significativamente a viabilidade celular em ambas as linhas 
celulares. De facto, o esperado aumento na viabilidade celular não ocorreu quando as células 
foram tratadas com acetato e com um ou mais inibidores das vias de síntese da ceramida. Mais 
estudos são necessários para confirmar os resultados obtidos, nomeadamente a determinação 
dos níveis celulares da ceramida e a actividade de enzimas envolvidas na síntese da mesma em 
células tratadas com acetato e um ou mais inibidores das vias de síntese da ceramida. 
Resumindo, os resultados obtidos até agora sugerem que a morte celular induzida pelo 
acetato em células HCT-15 e RKO de CCR parece não ser mediada pela ceramida.   
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1.1 Cancer: incidence, genetics and hallmarks 
 Nowadays, in the modern and developed countries and increasingly in developing 
nations, cancer is a disease with great incidence and affecting a growing number of people.  
In 2008, 12.7 million of new cases of cancer and 7.6 million cancer deaths were 
estimated, with 56% and 63% of new cases of cancer and cancer deaths, respectively, occurring 
in the less developed regions of the world (Ferlay, Shin et al., 2010). A new tendency has been 
noticed, while mortality rates are decreasing in many western countries, like the Unites States of 
America, this rate is growing in less developed and economically transitioning nations, due 
mostly to the adoption of unhealthy habits more known to western lifestyles (Jemal, Center et al., 
2010). More particularly, in Europe, 3.2 million of new cases of cancer and 1.7 millions of 
resulting deaths were estimated, being colorectal cancers the most common form of the disease 
found (13.6% of the total) and also the second most common cause of death (12.3% of the total) 
(Ferlay, Parkin et al., 2010).            
 Cancer is a complex disease with multiple causes. Nevertheless it could be defined as an 
atypical growth of cells, caused by several changes in gene expression leading to a disequilibrium 
between cell proliferation and cell death and, in some advanced cases, evolving into a population 
of cells capable of tissue invasion and metastization, far from the original location, resulting in an 
elevated morbidity and, if not treated, death of the host (Ruddon, 2007). 
 Several events are required to transform a normal cell into a malignant one and such 
process is called carcinogenesis. As a multi-step disease, cancer is caused by alterations that 
generally occur in somatic cells (although mutations in germ-line cells can also prompt a person 
to inherited cancer) affecting oncogenes, tumour suppressor and microRNA genes (Croce, 2008).   
 Some traits seemed to be shared by most forms of tumours. In fact, these acquired 
capabilities are the main consecutive alterations that enable carcinogenesis. There are six 
principal hallmarks that dictate cancer growth: sustaining proliferative signalling, evading growth 
suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and 
activating invasion and metastasis - Figure 1.1 (Hanahan and Weinberg, 2000). More recently, 
two other characteristics, involved in the pathogenesis of some and maybe all cancers, were 
added to the previous list, as emerging hallmarks: reprogramming of energy metabolism and 
evading immune destruction. Additionally, tumour-promoting inflammation and genomic 
instability and mutation are consequential properties of tumours that facilitate the acquisition of 
core and emerging hallmarks - Figure 1.1 (Hanahan and Weinberg, 2011).   
Chapter 1 – General Introduction 
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Figure 1.1 – The hallmarks of cancer, emerging hallmarks and enabling characteristics. Adapted from (Hanahan 
and Weinberg, 2011). 
 
1.2 Colorectal carcinoma  
Among all the different forms of cancer, colorectal carcinoma (CRC) has a great 
incidence and mortality in world population. According to the GLOBOCAN studies, in 2008, 
(Ferlay, Shin et al., 2010), CRC was the third most common type of cancer and the fourth cause 
of death, in both sexes, worldwide, with a major prevalence (60%) in developed countries.  
 There are two principal forms of colorectal cancer: the sporadic form and the inherited 
forms, which include the familial adenomatous polyposis (FAP) and the hereditary nonpolyposis 
colorectal cancer (HNPCC) (Potter, 1999).  
 The sporadic form is the most frequent form of colorectal cancer (70% of the cases), 
beginning from somatic mutations and evolving into a tumour. Inherited susceptibility to 
colorectal cancer may underlie 30% of all diagnosed types: 5% with an evident hereditary base 
predisposing to the disease and the remaining percentage only showing an elevated propensity of 
family members to be affected by the disease, without in fact presenting recognizable hereditary 
syndromes (Rustgi, 2007; Tops, Wijnen et al., 2009). FAP is an autosomal dominant inherited 
disease, characterized by the emergence of hundreds to thousands of adenomas or 
adenomatous polyps, during the second and third decade of patients’ lives. Even though these 
tumours are usually benign and individually not life threatening, some will eventually progress 
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and origin malignant forms of cancer (Kinzler and Vogelstein, 1996). HNPCC (or also called 
Lynch syndrome), is another inherited autosomal dominant syndrome, that exhibits a much less 
well characteristic phenotype than FAP and is often confused with sporadic polyposis (Potter, 
1999). HNPCC involves a predisposition not only to colorectal cancer, but also to other seven 
types of cancer, among them: the small bowel, endometrium, ovaries, stomach, brain, 
hepatobiliary epithelium and uroepithelial epithelium (Lynch, Guirgis et al., 1977). The FAP and 
HNPCC conditions account to 5% or less of total CRC cancers: less than 1% for FAP and, 
approximately, 5% for HNPCC (de la Chapelle, 2004). 
              
1.2.1 Colorectal carcinogenesis 
 Many genetic and structural alterations are necessary to the development of colorectal 
carcinoma. In 1990, Fearon and Vogelstein proposed a genetic model for colorectal 
tumourigenesis. That model evokes a sequential multistep changes, affecting several types of 
genes, represented in Figure 1.2, and that would consequently lead to progressive morphologic 
shifts of the colon and rectal apparatus (Fearon and Vogelstein, 1990).   
 
Figure 1.2 – Adenoma-carcinoma sequential model for chromosomal instability, in colorectal cancer. Adapted from 
(Walther, Johnstone et al., 2009). APC: adenomatous polyposis coli; TGFβ: transforming growth factor – β; MSI: 
microsatellite instability; CIN: chromosomal instability; MMR: mismatch repair; TGFβR2: transforming growth factor 
– β receptor 2; IGF2R: insulin-like growth factor 2 receptor.  
 To guarantee the CRC evolution, at least, four sequential genetic alterations or “hits” in 
specific oncogenes and tumour-suppressor genes need to occur. KRAS, an oncogene, and APC, 
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SMAD4 and TP53, three tumour-suppressor genes are the main targets of these changes (Fodde, 
Smits et al., 2001).  
The APC gene has a key role in CRC. Mutations of the germ-line in the APC gene are 
responsible for the FAP and are also found in non-hereditary colorectal cancers (Tanaka, 2009). 
The APC gene encodes a protein that has a preponderant role in Wnt signalling pathway, given 
that APC regulates cell proliferation. The mechanism by which this regulation is made depends 
on APC binding and degrading of β-catenin to promote cell proliferation (Ilyas, 2005). If APC is 
mutated this cannot occur and β-catenin is translocated to the nucleus, where it binds to a 
transcription factor (T-cell factor/lymphocyte enhancer factor). This will activate c-myc, cyclin D1 
and c-junc genes and induce cell proliferation (Tanaka, 2009).   
 Other important functions have been attributed to APC such as the control of intracellular 
adhesion, that might be achieved by regulating the stability and subcellular localization of β-
catenin (a constituent of adherens junctions), being the link between α-catenin and E-cadherin, 
that binds actin and its associated proteins (Ben-Ze'ev and Geiger, 1998). Furthermore, the direct 
association between APC with the microtubule cytoskeleton was also demonstrated (Munemitsu, 
Souza et al., 1994; Smith, Levy et al., 1994).  
 KRAS gene is also an important piece in the carcinogenesis process of CRC. It encodes a 
protein involved in G protein-mediated transduction. KRAS protein has a GTPase activity, which 
transmit signal across the cellular plasma membrane through the activation of the RAS-RAF-MEK-
ERK-MAPK signalling cascade (Roberts and Der, 2007). The most widespread types of KRAS 
mutation, in colorectal cancers, are the substitution of glycine to aspartate on codon 12 
(p.G12D), glycine to valine on codon 12 (pG12V) and glycine to aspartate on codon 13 (p.G13D) 
(Neumann, Zeindl-Eberhart et al., 2009). Mutation of KRAS is responsible for unregulated and 
increased cell proliferation and malignant transformation (Bos, 1989).   
 BRAF mutations have been identified in several types of human cancers, including 
colorectal tumours. The frequency of this mutation associated to CRC varies between 1% and 
20%, and BRAF mutation is specially connected to tumours with a dysfunction in mismatch repair 
(MMR) activity (Wellbrock, Karasarides et al., 2004). A transversion (T into A) is the most 
common BRAF mutation (90% of BRAF mutant tumours), originating a valine to a glutamic acid 
alteration - V600E (Davies, Bignell et al., 2002). In consequence, there is a major increase in in 
vitro kinase activity and the stimulation of cell proliferation and transformation (Wan, Garnett et 
al., 2004). Recently, it has been demonstrated that the inhibition of BRAF in CRC cell lines 
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interfered with the proliferation and apoptosis mechanisms. In BRAFV600E microsatellite unstable 
(MSI) cell lines, the suppression of BRAF, using the RNA interference technique, significantly 
induced apoptosis and inhibited proliferation. In contrast, no significant differences were 
observed in proliferation and apoptosis in cell lines harbouring a KRASG13D mutation, when 
submitted to BRAF inhibition (Preto, Figueiredo et al., 2008). Besides, the study from Preto and 
collaborators also found that, in BRAFV600E cell lines under BRAF inhibition, the levels of 
proliferation associated molecule p27Kip1 are increased and the levels of the anti-apoptotic protein 
Bcl-2 are decreased.  
The mutation of the TP53 gene is preponderant not only in CRC cases, but also in the 
majority of known cancers. It is thought to be a relatively late event in the carcinogenesis process 
of CRC and determinant in the progression from adenoma to a malignant tumour. This gene is 
mutated in up to 70% of colorectal cancers (Baker, Preisinger et al., 1990). In 1979, TP53 
tumour suppressor gene was the first one to be identified. It encodes a transcription factor - p53 
protein - implicated in cell cycle control. The p53 protein specifically binds to a recognition 
sequence in a variety of genes, including p21, Bax, and Bcl-2, when the DNA is damaged or the 
cell is under stress, if not the p53 network is usually not active (Vogelstein, Lane et al., 2000). 
p53 has a protective role toward cells, as well as a destructive one. Different stimuli, such as 
basal low-levels of p53, stress, DNA damage and oncogenic signals can all elicit the p53 system, 
resulting in different cell responses such as transient cell cycle arrest, autophagy, repair, 
apoptosis, senescence and necrosis. It is clear, that a shift in p53 output, from a death signalling 
to a repair one, can promote survival of mutated and damaged cells and increase the probability 
of tumour cell survival (Junttila and Evan, 2009).            
 The APC, KRAS, BRAF and TP53 are thought to be the major mutations found in CRC, 
but the carcinogenesis process is a complex set of events and all the interveners are not known. 
Additionally, we must be aware of the cross-talk between pathways that augment the 
tumourigenesis complexity. The more profound is our knowledge about CRC mutations, the 
bigger is the probability to find new strategies and new approaches to cancer therapy.  
  
1.2.2 Colorectal carcinoma: risk factors, prevention and therapy 
 The survival rates of CRC have significantly improved in the past years. The acquired 
knowledge about the disease, the prevention, the early detection and the development of 
treatments are fundamental reasons that sustain this increase.  
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A crucial part in the diminution of the CRC incidence is the identification of potential 
dangerous factors that contribute to the malady apparition. Risk factors behind CRC development 
can be divided in two categories: non-modifiable and modifiable risk factors. Non-modifiable risks 
factor are age and predispositions factors (incidental polyps, inherited disorders, inflammatory 
bowel disease, some of these already discussed in the last section). The major part of CRC cases 
occur in older individuals (age above 50 years), principally because the carcinogenesis process 
requires several mutations that gather over time. It is known that it would take up to ten years for 
cells to undergo significant mutations and become malignant (Scholefield, Ritchie et al., 2005). 
Interestingly ethnicity is also considered a non-modifiable risk factor for CRC. For example, the 
Ashkemazi Jews are a highly predisposed group in terms of the disease development, due to the 
I1307K APC mutation that runs among (6-7%) of the population (Locker, Kaul et al., 2006). 
Worldwide patterns and variations of CRC incidence are also consequence of modifiable 
risks. Obesity is an undeniable risk factor for CRC. Some studies showed that the body mass 
index (BMI) is connected to the incidence of CRC, and that risk suffers an elevation of 25% and 
50% in overweight and obese men, respectively (Moghaddam, Woodward et al., 2007). The link 
between the BMI and colorectal cancers seems to be weaker in women (Murphy, Calle et al., 
2000). If obesity is a risk factor, certainly the lack of physical activity is also a factor to be 
considered, as they are tightly linked. The presence of central adiposity and the absence of 
regular physical activity is associated with poorer survival rates, after CRC diagnosis (Haydon, 
MacInnis et al., 2006).  
 Diet has proven to be a decisive feature to either prevent or be, at least, in part 
responsible for the development of colorectal cancers. Currently, it is believed that a diet 
constituted of red meat with low portions of vegetables and fruits are likely to be increasing the 
risk of cancer (van Duijnhoven, Bueno-De-Mesquita et al., 2009).  
 The two last modifiable factor risks important to be referred are alcohol consumption and 
smoking. The uncontrolled alcohol consumption on a regular basis, as well as the habit of 
smoking, are thought to be associated with the increase in CRC incidence. An increased risk of 
16% and 41% is observed in individuals that drink 30-45 g/day and ≥45 g/day, respectively (Cho, 
Smith-Warner et al., 2004). Concerning the smoking, it very well known that several carcinogenic 
compounds are found in tobacco, being an important factor in CRC, despite being far more 
preponderant in other cancer types (Liang, Chen et al., 2009).     
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 Having in mind all the risks factors, prevention seems the best way to avoid and 
decrease the incidence of colorectal cancers. Several research works revealed that diet, as 
discussed above, could be important to prevent CRC and other form of tumours. Phytochemicals, 
included in the chemopreventive agent’s category, are found in vegetables and fruits and 
demonstrated to have a preventive effect on proliferation, to induce apoptosis and to inhibit 
growth factor signalling pathways. In addition, phytochemicals play a role in reversing 
chemoresistance and radioresistance, among other positive effects (Dorai and Aggarwal, 2004). 
A spice, curcumin, common in India has proven to be relevant in CRC prevention by promoting 
apoptosis, cell cycle arrest and participate in other essential pathways too (Johnson and Mukhtar, 
2007). Resveratrol (grapes), capsaicin (chilli peper) and gingerol (ginger) are all natural 
compounds able to stop tumour cell proliferation and malignant transformation by targeting and 
suppressing the overexpression of NF-κB (nuclear factor κB) and AP1 (activator protein 1) 
transcription factors, respectively (Surh, 2003). In addition, the dietary phytochemicals quercetin, 
luteolin and ursolic acid demonstrated to have anti-proliferative and pro-apoptotic effects on CRC 
derived cell lines (HCT-15 and CO115) and seemed to act on KRAS and PI3K. Quercetin and 
luteolin decreased ERK (extracellular-signal-regulated kinase) phosphorylation, in HCT-15 cells, 
while the three compounds led to decreased Akt phosphorylation on CO115 cells (Xavier, Lima et 
al., 2009). 
 A set of products called probiotics and prebiotics are thought to be relevant in the 
prevention of colorectal carcinoma, for example, the consumption of milk and its derivatives, 
products containing lactobacilli or bifidobacteria, seems to diminish the CRC incidence 
(Wollowski, Rechkemmer et al., 2001). Among the effects of pre and probiotics, that appear to 
reduce the risk of CRC, we can count the changes in the pH conditions in the colon, the lower 
production of probable carcinogenic product by gut microflora, the modulation of the immune 
response, the production of anticancer compounds, inter alia (Lim, Ferguson et al., 2005; 
Fotiadis, Stoidis et al., 2008).         
 Chemopreventive agents are also able to improve the efficiency of common cancer 
therapy i.e. the combined use of preventive agents and chemotherapy or radiotherapy (Sarkar 
and Li, 2006). Further investigation is needed to understand the mechanisms of synergy between 
chemopreventive agents and usual therapy, to take benefit of it.  
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1.3. Relation between intestinal flora and colorectal carcinoma 
 Human intestines are colonized by a large and diverse population of microorganisms. 
Bacteria are the predominant type and are indispensable for our survival and the healthy 
functioning of our organism. Gut microflora is responsible for multiple tasks as, for instance, 
saving nutrients and energy acquired from food, controlling the epithelial cell proliferation and 
differentiation, balancing the immune system homeostasis and protecting, in certain cases, 
against possible pathogens (Guarner and Malagelada, 2003).  
 The intestinal flora influence on colorectal carcinogenesis has become increasingly 
evident. Bacteria have been associated to CRC by production of toxic and genotoxic metabolites 
that affect intracellular signal transduction (Fasano, 1999). N-Nitroso compounds and bile acids 
are examples of such metabolites (Rowland, 2009). Other studies show that the metabolic 
activity of gut microbiota produces toxic products, such as reactive oxygen species (ROS), which 
lead to DNA damage and chronic inflammation contributing to tumourigenesis. Increasing 
findings demonstrated that the same agents are implicated in changes in host glycosylation, 
altering the cellular and sub-cellular distribution of glycans, and those alterations are linked to the 
neoplastic process (Hope, Hold et al., 2005).     
 On the other hand, short chain fatty acids (SCFAs) – acetate, propionate and butyrate – 
seem to have a protective effect against colorectal carcinoma (Scheppach, 1994), as it will be 
addressed in the next sections. 
  
1.3.1 Bacterial production of acetate in human gut 
A substantial part of carbohydrates consumed in human daily routine are fermented by 
several microorganisms in the colon. This is a result of the ingestion of cellulose (plant cell wall 
polysaccharides), hemicelluloses and pectins, vulgarly known as dietary fibre (Cummings, 1981). 
Bacteria present in human gut are capable of fermentation, not only of carbohydrates 
(polysaccharide and oligosaccharide) but also of proteins, peptides and glycoproteins precursors 
in the colon, resulting into pyruvate formation and its conversion into a series of intermediary and 
end products such as butyrate (butyric acid), acetate (acetic acid), propionate (propionic acid), 
carbon dioxide, methane, hydrogen and water (Miller and Wolin, 1979; Cummings, 1981). 
Between SCFAs products, acetate is the most produced (Cummings and Macfarlane, 
1991). There are a vast set of bacteria species involved in acetate formation; among them are 
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the following ones: Anaerotruncus colihominis, Bacteroides goldsteinii, Bifidobacterium, 
Cetobacterium somerae, Clostridium asparagiforme, Clostridium hathewayi, Dorea longicatena, 
Eubacterium, Lactbacillus, Streptococcus, Ruminococcus luti, and Victivallis vadensis (Miller and 
Wolin, 1979; Duncan, Louis et al., 2007).  
  Short chain fatty acids are absorbed in various zones of the colon and later metabolized 
at three specific sites in the organism: the ceco-colonic epithelium, the liver and muscles (Hijova 
and Chmelarova, 2007). Butyrate is used as a substrate to maintain the energy of producing 
pathways by cells belonging to the ceco-colonic epithelium. In the liver, SCFAs (residual butyrate 
and propionate) are metabolized and used in gluconeogenesis, also a great part of acetate (50% 
to 70%) is taken up by this organ. Additionally, a residual amount of acetate is utilized in muscle 
cells to generate energy from its oxidation. In general, SCFAs are important nutrients for the 
colonic epithelium cells. They have a role not only in the regulation of gene expression, cell 
proliferation and differentiation but also as modulators of colon ion transport, cell volume and 
intracellular pH (Cook and Sellin, 1998). As these compounds are rapidly absorbed in the colon, 
they are connected to bicarbonate excretion (Binder, Rajendran et al., 2005) and improve 
sodium absorption (Trinidad, Wolever et al., 1996).    
 Focusing in acetate metabolism, it is known that it is absorbed in the colon and 
transported to the liver. Once it enters the systemic circulation, acetate can be a part of 
lipogenesis that occurs in mammary glands (Hijova and Chmelarova, 2007). Acetate is the most 
abundant SCFA in the blood and it is the primary substrate for the synthesis of cholesterol, as 
well as it might be absorbed and used in peripheral tissues (Pomare, Branch et al., 1985). 
    
1.3.2 The role of acetate and other SCFAs in colorectal carcinoma cell death 
 As active compounds in the organism, SCFAs could have a beneficial effect on health 
especially in the fight against CRC. In fact, research on this area is evolving and every day a little 
more is known on the subject.  
 Sources of SCFAs that come from alimentation are nearly entirely dairy products. Once in 
the organism, they have numerous effects on colonic epithelial cells at different moments: 
growth, development, transformation and cell death (Cook and Sellin, 1998). Such interactions 
could explain the preventive effect of SCFAs on colorectal carcinoma (Figure 1.3).  
Studies support the notion that production of endogenous SCFAs might diminish the risk 
of cancer in colonocytes through processes such as apoptosis (Heerdt, Houston et al., 1994) and 
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regulation of histone acetylation (Hinnebusch, Meng et al., 2002). Some experiments realized 
with HT-29 cells, confirmed that butyrate and propionate are able to enhance histone acetylation 
and might contribute to biological effects connected to cancer prevention or progression (Kiefer, 
Beyer-Sehlmeyer et al., 2006). 
  
 
Figure 1.3 – Effects of short-chain fatty acids (SCFAs), on colonic epithelial cells, at different phases of the 
adenoma-carcinoma sequence. Adapted from (Scheppach, Bartram et al., 1995).  
  
On the other hand, programmed cell death is a fundamental process to keep the balance 
between cell generation and cell death. Interruption or defects on this process would alter this 
balance and favour tumour progression. All three major SCFAs, acetate, butyrate and propionate, 
have all proven to induce apoptosis in several adenoma and carcinoma cell lines, but butyrate 
seemed to be the most efficient and the most studied (McBain, Eastman et al., 1997; Cook and 
Sellin, 1998). Some interesting studies have been made showing, for instance, that 
propionibacteria are able to induce apoptosis, in vitro, in two colorectal carcinoma cell lines (HT-
29 and Caco 2) by means of acetate and propionate produced by fermentation (Jan, Belzacq et 
al., 2002). Two species of bacteria were object of the study P. acidipropionici and P. 
freudenreichii. The effects of propionate and acetate were tested alone or in combination, with a 
half maximal effective concentration (ED50) of 11 mM and 20 mM respectively, in HT-29 cells. 
The SCFAs-induced apoptosis was confirmed by the observation of ROS generation, caspase-3 
processing and nuclear chromatin condensation. In addition, the oncoprotein Bcl-2 (known to 
prevent apoptosis via mitochondria) and the viral mitochondrial inhibitor of apoptosis (vMIA), 
which interacts with the adenine nucleotide translocator (ANT), both inhibited cell death induced 
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by SCFAs, suggesting that mitochondria is decisively involved in this cell death process (Jan, 
Belzacq et al., 2002). Others studies also denote the induction of apoptosis of CRC cells by 
SCFAs (acetate and propionate) involving the mitochondria (Heerdt, Houston et al., 1997; Jan, 
Belzacq et al., 2002). It is evident that this process may be decisive in the attempt of finding a 
manner to prevent or treat colorectal cancers.  
Another investigation reinforces this finding demonstrating a main impact of a shift in 
extracellular pH, on the mode of propionibacteria SCFA-induced cell death of HT-29 cells, leading 
to SCFA-induced cell cycle arrest and apoptosis (Lan, Lagadic-Gossmann et al., 2007) and even 
leading to apoptosis in vivo (Lan, Bruneau et al., 2008). In 2007, Lan and collaborators 
demonstrated that P. freudenreichii SCFAs led to apoptosis and induced cell cycle arrest in G2/M 
phase prior to programmed cell death at pH 7.5. This pH also caused all typical morphological 
changes known in apoptosis (membrane blebbing, chromatin condensation and fragmentation, 
phosphatidylserine exposure and formation of apoptotic bodies). Otherwise at a pH of 5.5, the 
necrotic process was observed, in HT-29 cells, manifested by rapid swelling and disruption of 
internal organelles and plasma membrane lyses without chromatin fragmentation (Lan, Lagadic-
Gossmann et al., 2007). 
In 2008, Lan and co-workers also noticed that Propionibacterium freudenreichii could be 
able of not only killing cells in vitro, but also in vivo, with a remarkable selectivity. Apoptosis and 
proliferation of colonic epithelial cells were analysed in human microbiota-associated (HMA) rats, 
fed with P. freudenreichii TL133 strain on a daily routine, 48h hours after the induction of 
carcinogenesis with 1,2-dimethylhydrazine (DMH). The strain survived in the gastrointestinal tract 
of rats and demonstrated to induce apoptosis only in DMH-damaged cells, revealing the 
specificity of these bacteria protective role (Lan, Bruneau et al., 2008).  
Recent results, obtained by our laboratory, showed that SCFA and more particularly 
acetate is able to in induce apoptosis and to inhibit proliferation in HCT-15 and RKO CRC derived 
cell lines. This SCFA is also responsible for triggering lysosomal membrane permeabilization 
(LMP) and cathepsin D release to the cytosol (Marques, Oliveira et al., 2012 ; submitted).    
All the combined results showed above contribute to the idea that probiotics, such as 
propionibacteria and their respective metabolic products, could be used as strong agents for 
colorectal carcinoma prevention and perhaps therapy.  
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1.4 Apoptosis: the programmed cell death 
 Apoptosis is a cellular process of programmed cell death and is deeply important in 
development, immune response and tissue homeostasis. More and more studies link this 
process to the successful triggering of cancer cells death, namely CRC cells, when those seem 
“immortal”. 
 This type of death is characterized by a set of morphological changes beginning with cell 
shrinkage and chromatin condensation. Cell blebbing occurs and the “budding” process takes 
place, in other words, cell fragments are separated into apoptotic bodies that consists of 
cytoplasm (enclosed within an intact plasma membrane), containing tightly packed organelles 
with or without nuclear fragments (Elmore, 2007). These changes are caused by several cysteine 
proteases, known as caspases, that participate in two (intrinsic and extrinsic) pathways described 
for apoptosis (Figure 1.4).  
The intrinsic and extrinsic pathways of apoptosis differ in some points. The first pathway 
is activated by many different types of cellular stress, including some chemotherapeutic 
compounds, UV and γ-irradiation, reactive oxygen species (ROS), radicals generated as by-
product of normal cell metabolism, oncogene activation and DNA damage. Basically, the death 
stimuli origin comes from within the cell (Yang, Sales et al., 2009). Mitochondria has a central 
role in this pathway, as the apoptotic stimuli converge in the mitochondrial membrane 
permeabilization (MMP), releasing some pro-apoptotic proteins into the cytoplasm (such as 
cytochrome c), thereby triggering the activation of a cascade of caspases (Kroemer and Reed, 
2000; Riedl and Shi, 2004).  
On the other hand, the extrinsic pathway is activated by the so-called “death ligands”, for 
example, tumour necrosis factor-α (TNF-α) and TNF-α-related apoptosis-inducing ligand (TRAIL) 
(Yang, Sales et al., 2009). When they bind to their “death receptor”, a protein complex, called 
the death inducing signalling complex (DISC), is formed and the activation of the caspase 
cascade occurs (Riedl and Shi, 2004). In some cases, activation of caspase-8 directly leads to 
caspase cascade launch while, in other situations, caspase-8 modulates apoptosis through the 
cleavage of BH3 interacting-domain death agonist (BID), which in turn allows the MMP and 
consequent programmed cell death (Li, Zhu et al., 1998).   
The programmed cell death is object of a rigorous control. This regulation include 
proteins of the Bcl-2 family, that contains both agonists (Bax, Bak, Bad, Bcl-XS) and antagonists 
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(Bcl-2, Bcl-XL) of apoptosis (Ligr, Madeo et al., 1998). Those proteins also exercise control over 
MMP enhancing or inhibiting it (Kroemer, 2003).  
Besides mitochondria, other organelles and cellular compartments have been associated 
to the regulation of apoptosis: the endoplasmic reticulum (ER) and the lysosome.  
The stress upon the ER and its dysfunction (due to the accumulation and aggregation of 
unfolded proteins, for example) can result in cellular death, through apoptosis, if the stress is 
prolonged and the response fails restoring the normal ER function (Szegezdi, Logue et al., 2006). 
  
 
Figure 1.4 – Representation of the apoptotic intrinsic and extrinsic pathways. Adapted from (Calvino-Fernández 
and Parra-Cid, 2010).  
The lysosome is also involved in programmed cell death. In response of certain stimuli, 
including ROS, TNF receptor ligation, p53 activation and lipid second messenger sphingosine, 
lysosome partial membrane permeabilization has been shown to initiate an apoptosis response 
(Jäättelä, Candé et al., 2004; Boya and Kroemer, 2008). After stimulation, lysosomal membrane 
permeabilization (LMP) occurs through caspase-dependent mechanisms and releases cathepsins 
and other hydrolases in the cytosol (Kroemer, Galluzzi et al., 2007). It is thought that cathepsins 
are able to cleave Bid, leading to Bax activation and consequent release of apoptotic factors from 
mitochondria, initiating the programmed death of the cell (Cirman, Oresic et al., 2004). 
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1.4.1 Apoptosis in yeast and its relation to mammalian and colorectal 
carcinoma cells 
Over the years, the apoptosis process has been studied using a not so complex model 
such as the mammalian one: Saccharomyces cerevisiae has been largely used as a eukaryotic 
model for the understanding of programmed cell death.  
In S.cerevisiae, the apoptotic phenotype was found to be triggered by acetic acid (an end 
product of the alcoholic fermentation realized by this type of yeast), involving mitochondria and 
the release of cytochrome c in the process (Ludovico, Sousa et al., 2001; Ludovico, Rodrigues et 
al., 2002). It was also demonstrated that acetic acid had a stimulating effect on the 
mitochondrial outer membrane permeabilization (MOMP), requiring ADP/ATP carrier (AAC) 
proteins, which are orthologues of the adenine nucleotide translocator (ANT) of mammalian cells 
(Pereira, Camougrand et al., 2007).  Moreover, cell death triggered by acetic acid in yeast was 
found to be responsible for the Pep4p (orthologue of mammalian cathepsin D) translocation from 
the vacuole to the cytosol (Pereira, Chaves et al., 2010).  
The mechanisms described above, also happen in mammalian cells. It is believed that 
MOMP event is due, at least in part, to the formation of the permeability transition pore complex 
(PTPC), composed by several proteins, in which ANT and the voltage-dependent anion channel 
(VDAC) are included. The PTPC formation occurs between the two mitochondrial membranes, 
ANT and VDAC being located in the inner and the outer membrane, respectively (Halestrap, 
McStay et al., 2002). And with the opening of PTPC, proteins (such as cytochrome c) are 
released and apoptosis is engaged (Henry-Mowatt, Dive et al., 2004).  
The fact that similar events occurs both in yeast and mammalian cells is interesting, but 
is acetic acid/acetate capable of triggering such events in mammalian cells to? As mentioned in 
a previous section (1.3.2), evidences point to a certain kind of bacteria, more precisely 
propionibacteria, that are able to survive in the human intestines and kill colorectal carcinoma 
cells. These microorganisms, through their metabolism, produce metabolites, SCFAs (acetate, 
butyrate and propionate) that seem to be responsible for the death of CRC cells, by triggering 
apoptosis.  
In results obtained by our group, it was found that acetate lead to CRC apoptosis and 
that LMP and release of cathepsin D (to the cytosol) occurred in CRC cells undergoing apoptosis 
(Marques, 2010 ; Master thesis). The inhibition of cathepsin D with pepstatin A proved to lead to 
the increase in acetate-induced apoptosis in the HCT-15 and RKO CRC derived cell lines 
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(Marques, Oliveira et al., 2012 ; submitted). In a yeast model, in accordance with the 
mammalian studies, deletion of the Pep4p confers higher susceptibility to acetic acid, while the 
overexpression of this molecule confers higher resistance to yeast cells (Pereira, Chaves et al., 
2010). Thus, the role of cathepsin D may be protective over the process of acetate-induced 
apoptosis. Moreover, the overexpression of cathepsins have been linked to cancer, poor 
prognosis and higher risk of recurrence (Palermo and Joyce, 2008), although studies have been 
showing the emerging role of these proteases as tumour suppressor (López-Otín and Matrisian, 
2007).  
Every day, more and more is known about the mechanisms and routes of signalizations 
used by SCFAs to induce programmed cell death, but more studies are needed in order to unveil 
such processes and maybe provide a new strategy of CRC therapy/prevention. 
        
1.5 Ceramide: a lipid second messenger molecule 
 Ceramide belongs to the sphingolipid family and is considered as a biologically active 
molecule due to its role as lipid second messenger. Ceramide and other active sphingolipids are 
involved in the regulation of diverse cellular responses to exogenous stimuli (Spiegel, Foster et 
al., 1996). A regulating role has been attributed to ceramide in many signalling pathways 
involving the cell cycle, differentiation, senescence and apoptosis. This is the main reason why 
ceramide action and the regulation of its production have recently attracted the scientific 
community attention. In major part, effects of ceramide are antagonistic to growth and survival 
(Ruvolo, 2001).   
 
Figure 1.5 – Ceramide structure representation. Adapted from (Nelson and Cox, 2004).  
Sphingolipids molecules are constituents of all eukaryotes as membrane cells 
components and they can be found in milk fat globule membranes, skin lamellar permeability 
barrier and lipoproteins (Schmelz, 2004). Their basic constitution is one molecule of the long-
chain amino alcohol – sphingosine (or one of its derivatives) and a long-chain fatty acid. A polar 
head group is connected to the structure by a glycosidic or a phosphodiester linkage, according 
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to the situation. The ceramide formation occurs when a fatty acid is attached in an amide linkage 
to the –NH2, on the C-2 (Figure 1.5), and this represents the structural origin of all sphingolipids 
(Nelson and Cox, 2004). 
 
1.5.1 Ceramide synthesis: major biosynthetic pathways  
 Ceramide is the central point of sphingolipid metabolism. It serves as a crucial local of 
sphingolipid accumulation and it is a precursor for all major sphingolipids in eukaryotic cells. 
Synthesis of ceramide can occur through three major pathways: the de novo synthesis pathway, 
the sphingomyelinase (SMase) pathway and the salvage or sphingosine pathway (Reynolds, 
Maurer et al., 2004), represented in Figure 1.6. 
 
Figure 1.6 – Pathways of 
sphingolipid metabolism. Adapted 
from (Ogretmen and Hannun, 2004). 
The de novo pathway (pink); 
sphingomyelinase (SMase) pathway 
(blue); salvage pathway (orange); 
cerebrosides (green). Ceramidases, 
CDases; sphingosine kinases, SKs; 
sphingosine-1-phosphate, S1P; C1PP, 
ceramide-1-phosphate phosphatase; 
CRS, cerebrosidase; CK, ceramide 
kinase; CS, ceramide synthase; DAG, 
diacylglycerol; DES, dihydroceramide 
desaturase; GCS, glucosylceramide 
synthase; PC, phosphatidylcholine; 
S1PP, S1P phosphatase; SMS, 
sphingomyelin synthase; SPT, serine 
palmitoyltransferase.  
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1.5.1.1 The de novo synthesis pathway 
The de novo pathway begins with the condensation reaction between the amino acid 
serine and palmitoyl-CoA resulting in 3-ketosphinganine formation. After that, the compound is 
reduced by the 3-ketosphingamine reductase enzyme, forming sphinganine and, by the action of 
ceramide synthase, dihydroceramide is formed. Finally, dihydroceramide is converted into 
ceramide, adding to it a trans-4,5 double bond, by the action of a desaturase  (Merrill, 2002). In 
an alternate manner, this pathway may re-utilize sphingosine released after the degradation of 
more complex sphingolipids (Reynolds, Maurer et al., 2004).  
The de novo synthesis is believed to occur in the endoplasmic reticulum (ER) and 
probably in ER-associated membranes including the perinuclear membrane and mitochondria-
associated membranes – MAMs (Hannun and Obeid, 2008).  
The stimulation of the pathway can be achieved by drugs and ionizing radiation that 
normally results in a prolonged ceramide elevation (Liao, Haimovitz-Friedman et al., 1999). Some 
chemotherapeutic agents can also enhance the de novo pathway stimulation; etoposide and 
daunorubicin are examples of them (Bose, Verheij et al., 1995; Perry, Carton et al., 2000) . 
Others inducers of apoptosis like the B-cell receptor, seem to have the same activating effect 
(Kroesen, Jacobs et al., 2003). Obviously, the metabolic loading of either serine or palmitate can 
lead to ceramide production, as well as oxidized low-density lipoprotein - LDL (Kitatani, Nemoto et 
al., 2002), cannabinoids (Gómez del Pulgar, Velasco et al., 2002) and heat stress (Jenkins, 
Cowart et al., 2002). Studies realized have largely implicated this pathway in mediating some 
effects of the inducers, described above, on stress responses and apoptosis (Kitatani, Idkowiak-
Baldys et al., 2008). 
       
1.5.1.2 The sphingomyelinase pathway 
 Ceramide can be generated through the activation of sphingomyelinases (SMases), a 
special class of phospholipid phosphodiesterases, found in cell membranes. These enzymes are 
responsible for hydrolyzing sphingomyelin to originate ceramide and phosphocholine (Jones, 
Hannun et al., 2005).   
Different types of SMases exist, differentiated mainly by their optima (acid, neutral or 
alkaline) pH. The acid SMase (aSMase) has an optimum pH between 4.5 and 5.0 and was 
initially considered to be strictly located in the lysosome. Nevertheless, an isoform has been 
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described to be present in vesicles near the plasma membrane and, under certain conditions, 
the aSMase could also relocate to the outer leaflet of the plasma membrane (Grassmé, Schwarz 
et al., 2001; Hannun and Obeid, 2008). Furthermore, aSMase was shown to be secreted 
extracellularly (Schissel, Keesler et al., 1998). In sum, there may be three types of aSMase: the 
acidic lysosomal aSMase (responsible for the sphingomyelin metabolism), the secretory aSMase 
(associated with inflammation and stress responses) and the receptor-activated aSMase (that 
translocates to the outer cell membrane, after activation by various cell surface receptors and 
hydrolyzes membrane sphingomyelin into ceramide).  
 Two neutral SMases (nSMases) have been identified: nSMase1 and nSMase2. Although 
both proteins are capable of converting sphingomyelin into ceramide, evidences are against a 
role for nSMase1 in regulating this reaction in cells (Tepper, Ruurs et al., 2001). The nSMase2 
has an optimum pH of 7.4 and appears to be localized to the inner leaflet of the plasma 
membrane (Hannun and Obeid, 2008).    
 The alkaline SMase (alk-SMase) has an optimal alkaline pH at 9 and its activity is 
dependent on bile salts (Hertervig, Nilsson et al., 1997). This enzyme is expressed in the 
intestinal mucosa in many species and human bile too. In the intestinal tract, alk-SMase activity 
is superior in the jejunum and lower in the duodenum and colon, being responsible for the 
hydrolysis of dietary sphingomyelin (Duan, 2006).  
 Sphingomyelinase pathway is stimulated in response to cell treatment with TNF-α, Fas 
ligand or oxidative stress (Hannun, Luberto et al., 2001; Marchesini and Hannun, 2004). 
   
1.5.1.3 The salvage or sphingosine pathway 
 Another important mechanism for ceramide generation is the salvage pathway, in which 
sphingosine (produced from the metabolism of complex sphingolipids, mostly in the lysosome) is 
re-cycled to ceramide, localized then in the ER or associated membranes (Hannun and Obeid, 
2008). Various enzymes are part of this pathway including ceramidases, (dihydro)ceramide 
synthase, SMases and probably glucocerebrosidase (acid-β-glucosidase).  
This alternative via of ceramide generation is thought to be crucial for sphingolipid 
breakdown, in sphingolipid synthesis/turnover as well as in cellular signal transduction. These 
assumptions are based on the fact that the salvage pathway, leading to the re-regeneration of 
sphingolipids, has been estimated to contribute in 50% to 90% in sphingolipid biosynthesis 
(Tettamanti, Bassi et al., 2003). 
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Salvage pathway is stimulated in response to cell treatment with TNF-α (Kim, Linardic et 
al., 1991), Fas ligand (Brenner, Ferlinz et al., 1998) or oxidative stress (Goldkorn, Balaban et al., 
1998). 
    
1.5.2 Inhibitors of ceramide biosynthesis 
 Certain compounds and molecules have an inhibitory action upon ceramide synthesis 
and are able to stop those pathways at different levels. The same effect can be obtained using 
other techniques such as the knockdown of a particular enzyme of the pathway, or using 
microRNA. Some noteworthy inhibitors will be briefly described below.   
 Ceramide de novo synthesis can be inhibited at the serine palmitoyltransferase (SPT) 
level by an antifungal molecule called sphingofungin B (Zweerink, Edison et al., 1992). Myriocin, 
an antifungal antibiotic, also stops the action of SPT. It was described as possessing 
immunosuppressant properties (Miyake, Kozutsumi et al., 1995) and, after some developments, 
an analogue of this molecule was created – FTY720 (Adachi, Kohara et al., 1995).     
 Fumonisins (Desai, Sullards et al., 2002), originated by Fusarium verticilioides and 
Fusarium moniliforme; the fumonisins related AAL-toxins, produced by the fungus Alternaria 
alternata (Winter, Gilchrist et al., 1996); australifungins (Mandala, Thornton et al., 1995), 
micotoxins coming from Sporormiella australis are among the most studied inhibitors of 
ceramide synthase (CerS). Among all, fumonisin B1 (FB1) is the most representative member of 
this class of compounds. This molecule is a powerful inhibitor of CerS, acting in both de novo 
and salvage pathways of ceramide production (Kitatani, Idkowiak-Baldys et al., 2008). 
 Inhibition can also happen in the SMase pathway, by cessing the activity of the different 
SMases. For example, desipramine is a tricyclic antidepressant that acts upon aSMase inducing 
its proteolysis (Elojeimy, Holman et al., 2006). Several compounds have been described as 
inhibitors of nSMase. Manumycin A irreversibly inactive the nSMase (Arenz, Thutewohl et al., 
2001) while Scyphostatin has a reversible effect, but also reversibly inhibits the aSMase (Nara, 
Tanaka et al., 1999; Arenz and Giannis, 2000). Sphingolactones, a new family of molecules, are 
also reported as irreversible inhibitors of the neutral SMase (Wascholowski and Giannis, 2006). 
During a high throughput screening on Mg2+ dependent nSMase, a compound called GW4869 
was discovered and exhibited inhibitory properties against this enzyme (Delgado, Casas et al., 
2006).  
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1.5.3 Role of ceramide in vital cellular processes and apoptosis 
 Sphingolipid metabolism and, more particularly, ceramide have been implicated in many 
cellular processes. Ceramide has been seen as a coordinator of cellular stress responses, taking 
part of mechanisms as the cell cycle, differentiation, cell senescence and apoptosis.  
During a growth phase, ceramide and phosphatidylcholine are converted into 
sphingomyelin (Hannun, 1994) and diacylglycerol (DAG), a product of this reaction, is a strong 
protein kinase C (PKC) activator (Nishizuka, 1995). This activation of PKC pathways by DAG 
sustain cell survival (Ruvolo, 2001). On the opposite, upon stress conditions, ceramide is 
produced by the breakdown of sphingomyelin (by SMases) (Hannun and Luberto, 2000). 
Sphingomyelin synthase appears to regulate DAG and ceramide possibly balancing the fate of 
cells between growth and apoptosis (Luberto and Hannun, 1998).  
 Some studies reported that differentiation of leukaemia cells happened when they were 
treated with ceramide and its analogues, imitating the effects of TNF-α, 1α, 25-dihydroxyvitamin 
D3 and γ-interferon, on the cell line studied (Okazaki, Bielawska et al., 1990).  
 Ceramide also demonstrated to be important when cells enter in the senescence phase, 
since its quantity increases (4-fold) in a human fibroblast cell line (Venable, Lee et al., 1995), but 
much remains to be elucidated about the mechanisms behind those observations. 
 Autophagy is a vital procedure in a living cell and it has also been connected to 
ceramide. Some models have shown that ceramide-induced autophagy is a response to 
starvation, resulting from nutrient transporter downregulation (Peralta and Edinger, 2009). 
Moreover, ceramide-mediated macroautophagy resulted in up-regulation of beclin 1 and inhibition 
of protein kinase B - PKB (Scarlatti, Bauvy et al., 2004). Besides, after proving that ceramide 
signalling occurs through the activation of Akt/PKB, upstream of mTOR, it was shown that 
ceramide stimulates JNK1 to phosphorylate Bcl-2, after dissociation of beclin 1 (Pattingre, Tassa 
et al., 2005; Pattingre, Bauvy et al., 2008; Pattingre, Bauvy et al., 2009).  
 Over the years, ceramide role in apoptosis has attracted many attentions due to the 
finding of its pro-apoptotic role.  
Environmental stresses and several cytokines (that trigger apoptosis) such as TNF, 
CD95/Fas/APO-1, ultraviolet-C, ionizing radiation, oxidative stresses, heat shock, 
chemotherapeutic agents, among others, appear to quickly induce ceramide production (Pettus, 
Chalfant et al., 2002). In fact, it is important to refer that the doses of these agents necessary to 
produce ceramide are really close to those required to induce apoptosis (Kolesnick and Kronke, 
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1998). Also, that the elevation of cellular concentration of ceramide, in response to those agents, 
occurs prior to the execution phase of apoptosis (Birbes, El Bawab et al., 2002). Another 
interesting notion about cell-permeable ceramide and analogues is that its exogenous 
administration induces apoptosis in multiple cell types (Cifone, De Maria et al., 1994; Jarvis, 
Kolesnick et al., 1994). Furthermore, apoptosis can be inhibited by stopping ceramide 
production and cells that cannot generate ceramide are unable of undergoing programmed cell 
death (Selzner, Bielawska et al., 2001). Otherwise, in cancer cells, apoptosis can be induced by 
the elevation of ceramide levels, using inhibitors of ceramide synthesis or by externally adding 
cell-permeable ceramide analogues (Selzner, Bielawska et al., 2001; Siskind, 2005). 
Notwithstanding all the studies that have been made, in order to understand by which 
process ceramide generation can trigger apoptosis, the subject remains not fully understood. 
Some direct and probable targets of ceramide action have been found (Figure 1.7) and, among 
them, some that combine ceramide formation with downstream inducers of programmed cell 
death are the following ones: cathepsin D, ceramide activated protein kinases (CAPK) and 
serine/threonine protein phosphatase 1 (PP1) and serine/threonine protein phosphatase 2A 
(PP2A) (Heinrich, Wickel et al., 2000; Pettus, Chalfant et al., 2002). Additionally, ceramide and 
its metabolism might be associated to LMP induction and the activation of the lysosomal 
cathepsin D (Benes, Vetvicka et al., 2008). 
As observed in Figure 1.7, many pathways are involved in ceramide-induced apoptosis. 
Ceramide action towards mitochondria has been studied. Ceramide activated protein 
phosphatases (CAPP) are responsible for dephosphorylating Bcl-2 and Bcl-2 kinase PKCα, both 
acting on this organelle. As the Bcl-2 function is to inhibit the cytochrome c release, it has been 
suggested that mitochondrially generated ceramide leads to cytochrome c release and, in 
consequence, to programmed cell death (Kagedal, Johansson et al., 2001; Pettus, Chalfant et 
al., 2002).  
Others interactions have been taken in consideration. Proteins p53 and Rb 
(retinoblastoma protein) seem to act along with ceramide generation, upstream of ceramide 
production for p53 and downstream for Rb that is dephosphorylated by CAPPs. In cell lines 
where agonists do not seem to trigger programmed cell death, Rb associated with ceramide is 
involved in cell cycle arrest, which could explain the reason why sometimes apoptosis is activated 
and, in other situations, only cell cycle arrest is observed (Alberts, Thorburn et al., 1993; Dbaibo, 
Pushkareva et al., 1995).   
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Figure 1.7 – Ceramide effector pathways relevant to apoptosis. Adapted from (Pettus, Chalfant et al., 2002). 
 
 Upon stimulation (by FAS or chemotherapy, for example) apoptosis can be induced by 
the action of cathepsin D, which could, in turn, have been triggered by ceramide (Heinrich, 
Wickel et al., 2000). The same outcome can be obtained by stimulation of TNF receptors. 
Endosomes are formed after internalization and then fused with lysosomes generating 
multilamellar bodies, contacting directly with lysosomal aSMase. The TNF-receptor activates 
aSMase, releasing intra-vesicular ceramide that binds cathepsin D. The last one translocates to 
the cytoplasm where it triggers cell death via Bid, Bax and Bak molecules (Schneider-Brachert, 
Tchikov et al., 2004).  
 Another mechanism by which ceramide-induced apoptosis could be achieved has been 
described. Thus, death receptors CD95 and DR5, in an activated state, trigger the translocation 
of aSMase to the extracellular leaflet of the plasmatic membrane, which leads to the formation of 
ceramide-enriched membrane platforms (sphingomyelin transformed into ceramide by aSMase). 
This leads to the re-organization of CD95 and DR5 in small clusters. Despite not being completely 
understood this process has revealed to be necessary for an efficient signalling, of these 
receptors, leading to programmed cell death (Carpinteiro, Dumitru et al., 2008).  
 Many “routes” seem to lead to apoptosis in ceramide behalf, but more investigation in 
that field is needed to better understand in which precise conditions and by what processes 
programmed cell death is activated. 
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1.5.4 Role of ceramide in colorectal carcinoma 
As mentioned previously, resistance to cell death is one of the cancer hallmarks. 
Ceramide and its analogues have proved that they were capable of inducing cell death, namely 
apoptosis, in several types of cells, including CRC. It is known that the levels of ceramide in CRC 
are lowered in 50% and, also, that the application of ceramide and analogues induce apoptosis 
via caspases and the release of cytochrome c (Selzner, Bielawska et al., 2001). 
 In CRC cell lines, such as HT-29 and HTC-116, ceramide and sphingoid bases caused 
cell death (Ahn and Schroeder, 2002). In addition, C2-ceramide treatment of cells that harbour 
the APC gene induced apoptosis through ceramide, mediated via a reduction in the levels of this 
gene (Jaiswal and Narayan, 2004). 
 Ceramide has the potential of being used as a treatment to CRC and other forms of 
tumours. Increasing intracellular ceramide levels could be used to reach growth arrest and 
activate apoptosis in malignant cells. In contrast, diminishing ceramide levels would work in 
favour of proliferation (Kolesnick, 2002).  
   As aforementioned, cellular stress increase ceramide levels in cells, in consequence 
chemotherapeutic agents (radiotherapy, etoposide, vincristine, fenretinide, irinotecan, etc.) also 
have the same effect (Senchenkov, Litvak et al., 2001). Maybe the use of strategies interfering 
with the inhibition of ceramide generation could sort some effect, as it happened with the 
ceramidase inhibitor B13 for example, that raised the cellular content in ceramide, led to the 
rapid release of cytochrome c, the activation of caspase 3 and specifically induced cell death of 
cancer cells, without affecting healthy ones, in vivo (Selzner, Bielawska et al., 2001). In 
experiences realized in an in vivo model (nude mice), B13 also prevented the growth of 
aggressive forms of human colon cancer. Cancer cells were injected in nude mice and some 
weeks after the injection tumour growth was determinate; the majority of animals that received a 
B13 treatment remained completely cancer free (Selzner, Bielawska et al., 2001). Interrupt the 
S1P synthesis (pro-survival molecule) could also be an interesting method to test, as it could help 
triggering ceramide-mediated programmed cell death (Reynolds, Maurer et al., 2004). 
 A lot of strategies to fight cancer could be used but betting in mechanisms that could 
lead to the specific death of cancer cells is the major objective. Ceramide has reunited good 
evidences to become a part of such strategies but, in the meantime, much more investigation 
need to be done to really understand how this secondary messenger could be manipulated in 
order to achieved such goal. 
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2.1 Rationale of the project  
Colorectal carcinoma is a common form of tumour and one of the most impacting 
worldwide. Propionibacteria are a group of microorganisms that live in the human organism and 
as a result from their metabolism short-chain fatty acids are produced, among them are acetate, 
butyrate and propionate. In 2002, Jan and co-workers demonstrated that SCFAs were able to 
induce cell death in colorectal carcinoma cells by apoptosis, without affecting healthy cells. It was 
also suggested that mitochondria would have a role to play in this cell death pathway (Jan, 
Belzacq et al., 2002). More recently, similar results were obtained by other research groups, 
linking SCFA-induced apoptosis to environmental factor such as the pH (Lan, Lagadic-Gossmann 
et al., 2007) and unveiling the deadly action of SCFAs in vivo (Lan, Bruneau et al., 2008).      
 Studies carried using the yeast Saccharomyces cerevisiae demonstrated that acetic acid 
could trigger the programmed cell death in yeasts associated with mitochondria and the release 
of cytochrome c (Ludovico, Sousa et al., 2001; Ludovico, Rodrigues et al., 2002). Furthermore, 
apoptosis induced by acetic acid was also found to be connected to the Pep4p (orthologue of 
mammalian cathepsin D) translocation from the vacuole to the cytosol. The mechanisms that 
occur in yeasts are often similar to those happening in more complex organisms, but is acetic 
acid/acetate able to determine such events in mammalian cells? Recent experiments realized in 
our laboratory demonstrated that apoptosis was activated by acetate in CRC cell lines and that 
same compound led to lysosomal membrane permeabilization (LMP) and release of cathepsin D 
to the cytosol (Marques, Oliveira et al., 2012 ; submitted).  
 Sphingolipids, namely ceramide, play a role in a variety of cellular responses including 
cell growth, differentiation, senescence and cell death. Moreover, ceramide proved to have a 
determinant role in the induction of apoptosis in colorectal carcinoma cells (Ahn and Schroeder, 
2002) and this molecule and its metabolism might be associated to LMP induction and the 
activation of the lysosomal cathepsin D (Benes, Vetvicka et al., 2008).  
 The involvement of ceramide as a mediator of the acetate-induced cell death, in CRC cell 
lines, has not been investigated. As aforementioned, it has been described that acetate induce 
apoptosis in CRC cells and that ceramide also had a role on the process. Therefore, the 
possibility of the programmed cell death triggered by the SCFA being associated to ceramide 
metabolism was a good relation to be exploited. Certainly, understanding this process will lead to 
a new therapeutic strategies and help improving existent ones. 
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2.2 Objectives  
Ceramide, as an important secondary messenger, and its metabolism seem to be 
interconnected to many major cellular processes. Evidences collected over the years, by our 
research group and other teams, point that this relation might be also present in acetate-induced 
apoptosis observed in colorectal carcinoma cell lines.   
Consequently, the objective of this project was to understand the role of ceramide in 
acetate-induced cell death in CRC cells. More particularly, the aim was centred in elucidating the 
involvement of ceramide and its synthesis pathways in the activation of apoptosis, triggered by 
acetate in colorectal carcinoma cell lines. 
Bearing in mind this general goal, we specifically aimed at: 
1. Establish the half maximum inhibitory concentration (IC50) of acetate, and determine the sub-
lethal concentration of the ceramide metabolism inhibitors, for each cell line used. 
2. Study the role of the different biosynthesis pathways of ceramide in acetate-induced cell 
death in CRC cells by assessing the effect of inhibiting the sphingomyelinase (SMase) 
pathway, the salvage pathway and the de novo synthesis pathway of ceramide, using 
pharmacological inhibitors of specific steps of ceramide metabolism. 
  
 
 
 
3 
Material and Methods 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3 – Material and Methods 
33 
 
3.1 Cell culture: cell lines and culture conditions 
To fulfil the objectives of the present work, two different cell lines were used: HCT-15 
(CCL-225) and RKO (CRL-2577), from the American Type Culture Collection (ATCC), that were 
kindly provided by the Institute of Molecular Pathology and Immunology of the University of Porto 
(IPATIMUP). Both cell lines were originated from colorectal carcinoma, but harbour different 
genetics backgrounds.  
HCT-15 cell line was derived from a human colorectal adenocarcinoma (Dukes’ type C) 
and was established by Jean C. Hager, from solid tumour material obtained during surgery and 
before drug treatment (Tibbetts, Chu et al., 1977; Dexter, Barbosa et al., 1979). These cells 
harbour several mutations, including a KRAS G13D and a TP53 mutation (Küntzer, Eggle et al.; 
Preto, Figueiredo et al., 2008). HCT-15 cells were grown in RPMI 1640 (with stable glutamine) 
medium (PAA, Austria), supplemented with 10% (v/v) heat inactivated fetal bovine serum (FBS; 
Sigma, USA) and 1% (v/v) penicillin-streptomycin (5,000 Units/mL of penincilin and 5,000 
µg/mL of streptomycin; Gibco, Invitrogen). 
RKO cell line was originally extracted from a primary colon carcinoma and was developed 
by Michael Brattain (Brattain, Levine et al., 1984). RKO harbours five main gene mutations, 
including a BRAF V600E   mutation (Küntzer, Eggle et al.; Preto, Figueiredo et al., 2008). These cells 
were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM; PAA, Austria), supplemented with 
10% (v/v) heat inactivated fetal bovine serum (FBS; Sigma, USA), 1% (v/v) penicillin-streptomycin 
(5,000 Units/mL of penicillin and 5,000 µg/mL of streptomycin; Gibco, Invitrogen) and 2% (v/v) 
of sodium bicarbonate 7.5% (Gibco, Invitrogen).  
 Both cell lines were grown and maintained in 25 cm2 tissue culture flasks (TPP), in a 
humidified incubator at 37ºC, containing 5% of carbon dioxide (CO2). Renewal of the medium was 
effectuated 1 or 2 times per week, and the cells were sub-cultured when the confluence reached 
80%-100%.  
The sub-culture was initially performed by removing the medium, contained in the culture 
flask, and cells were washed twice with 1mL of PBS (phosphate buffered saline) 1x solution. In 
order to detach the adherent cells from the flask, they were incubated with 0.5 mL of a 0.05% 
trypsin-0.02% EDTA solution (Gibco, Invitrogen), at 37ºC, in a 5% CO2 atmosphere, for a few 
minutes (depending on the cell type), to help the reaction. After cell detachment, 4.5 mL of fresh 
and supplemented medium were added to neutralize the trypsin effect and obtain a cell 
suspension. Cells were then seeded in 25 cm2 flasks at the desired density, using fresh medium.   
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3.2 MTT reduction assay  
The MTT reduction assay is one of the most common techniques used in cell biology for 
the quick assessment of cell viability and proliferation (Mosmann, 1983). It is also widely used as 
an assay to determine compounds cytotoxicity, for example, the chemosensitivity of a particular 
cell type to anticancer drugs (Carmichael, DeGraff et al., 1987).  
The method’s principle consists in the reduction of the tetrazolium salt thiazolyl blue, 
also termed MTT, from methyl-thiazolyl-tetrazolium (3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide), in formazan, a water insoluble and (purple) coloured compound, 
which can be spectrophotometrically quantified (Figure 3.1). This reaction only occurs in cells 
with metabolic activity, and the amount of formazan crystals formed is directly proportional to the 
quantity of viable cells (Belyanskaya, Manser et al., 2007).  
 
 
 
Figure 3.1 – (A) Representation of the chemical structure of MTT and its reduced formazan product; (B) 
absorption spectra of MTT and MTT formazan, in distilled water and sunflower oil, respectively, both at the same 
concentration (0.016 mg/ml). Adapted from (Stockert, Blázquez-Castro et al., 2012). 
  
Despite of being widely used, the mechanism of MTT reduction is poorly understood, 
neither the subcellular localization, nor the biochemical events are fully known. It was initially 
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assumed that the reduction of MTT was accomplished by mitochondrial enzymes, being MTT 
reduction supported by the specific substrate succinate, on active mitochondria of living cells, as 
demonstrated by Slater and co-workers, using rat liver homogenates (Slater, Sawyer et al., 
1963). Nevertheless, other studies showed that this reaction could also be carried by 
nonmitochodrial enzymes, such as dehydrogenases or flavin oxidases, and that NADH or NADPH 
are better substrates in MTT reduction than succinate (Liu, 1999). MTT reduction could be 
carried in the cytoplasm by NADH and by dehydrogenases associated to the endoplasmic 
reticulum (Berridge, Tan et al., 1996), in the plasma membrane (Bernas and Dobrucki, 2000) 
and endosome/lysosome vesicles (Bernas and Dobrucki, 2002).  
It was also postulated that MTT is non membrane permeable and, therefore, it enters the 
cells by endocytosis. Furthermore, its reduction would be performed by a N-ethylmaleimide-
sensitive flavin oxidase and the intracellular formazan granules formed would accumulate in 
endosomal or lysosomal vesicles and ultimately be transported outside of the cell by exocytosis, 
under the aspect of needle-like crystals (Liu, Peterson et al., 1997). However, other hypothesis 
are supported to explain the efflux of formazan, such as physico-chemical interactions at 
molecular level (Diaz, Melis et al., 2007). Despite MTT reduction mechanism still remaining 
partially unclear, it is a valuable tool to determine cellular viability.        
 To perform MTT assays, cells were seeded in 96-well plates at a final cellular density of 
1x104 cells/well for HCT-15 cell line and 7,5x103 cells/well for RKO cell line, with a final volume 
of 100 µL per well. Cells were incubated overnight, between 16h to 24h, in a 37ºC incubator, 
with a 5% CO2 and humidified atmosphere, to promote cellular adhesion to the plate. After that, 
the intended treatment was applied to the cells (conditions were performed in triplicate). For this 
purpose, the medium was removed, allowing the removal of dead cells, and replaced with fresh 
medium in which the desired compounds were added. Cells were maintained in the incubator, in 
the same conditions as cited above, during 48h.    
At this time point, 10 µL of MTT solution (Sigma, USA), prepared at a concentration of 5 
mg/mL in PBS 1x (pH 7.4) and maintained in the dark, was added to each well, resulting in a 
final concentration of 0.5 mg of MTT per mL. The 96-well plate was wrapped with aluminium foil 
and re-incubated for a 4 hours period, allowing the metabolism of MTT and formation of visible 
formazan crystal. These crystals were solubilised by adding a solubilisation solution (89% 
isopropanol, 10% Triton-X and 1% of HCl 37%) and each well was ressuspended. After all crystals 
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were completely dissolved the absorbance was read in a microplate reader (SpectraMax Plus384 
Microplate Reader – Molecular Devices) at a wavelength of 570-690nm (690nm reference value).  
 When seeded in 24-well plates, the protocol used was slightly different. A final cellular 
density of 2,5x104 and 7x104 cells/well was used for RKO and HCT-15 cell lines, respectively, 
with a final volume of 1 mL per well. After being seeded, cells were incubated and the desired 
treatment was applied in the same conditions as described above. At the required time point 
(48h), cell medium was removed and cells were rinsed, once, with 1 mL of sterile PBS 1x and  
0.5 mL of MTT solution (0.5 mg/mL in PBS 1x pH 7.4) was added to each well (this solution was 
prepared just before its usage and maintained in the dark). Following that, the cell culture plates 
(wrapped in aluminium foil) were incubated in a 37ºC incubator, with a 5% CO2 and humidified 
conditions, for 2 hours.  
After allowing the formation of formazan crystals, 0.5 mL of acidic isopropanol (0.04 M 
HCl in absolute isopropanol) were added to the wells, in order to dissolve the formazan crystals. 
The plates, always protected from light, were placed in an orbital shaker for 30 minutes to help 
the dissolution of the formazan crystals. With a micropipette, each well was homogenised, to 
solubilise the remaining crystals, and 0.2 mL were transferred to a 96-well cell culture plate. 
Absorbance was also read in a microplate reader (SpectraMax Plus384 Microplate Reader – 
Molecular Devices) at a wavelength of 570-690nm (690nm reference value).  
The results obtained were expressed as a percentage of cell viability in relation to the 
negative control (untreated cells). 
           
3.3 Cell treatment with acetate and ceramide pathway inhibitors: GW4869, 
fumonisin B1 and myriocin   
 In the attempt to verify if ceramide is involved in acetate-induced apoptosis, HCT-15 and 
RKO cell lines were pre-treated with inhibitors of the ceramide pathways before induction of cell 
death by incubation with acetate and in the absence or presence of acetate (co-incubation). The 
analyses were performed using 96-well plates and the cellular viability was determined by MTT 
assay.  
 Three different inhibitors were used (Figure 3.2). GW4869 (C30H28N6O2 · 2HCl · xH2O; 
Sigma, USA) is a drug that impedes the action of neutral sphingomyelinase (nSMase), interfering 
in the sphingomyelinase (SMase) pathway; fumonisin B1 - FB1 - (C34H59NO15; Enzo Life Sciences), is 
an inhibitor of ceramide synthase (CerS), acting in the salvage pathway of ceramide biosynthesis 
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and myriocin (C21H39NO6; Enzo Life Sciences) inhibits the action of serine palmitoyltransferase 
(SPT), at the de novo synthesis pathway of ceramide biosynthesis (Figure 3.3). 
GW4869 was dissolved in dimethyl sulfoxide (DMSO) at a 20 mM stock concentration 
and stored at -20ºC, while fumonisin B1 was dissolved in sterile ultra-pure water at a 20 mM stock 
concentration and also stored at -20ºC. To determine the higher concentration that would have 
less toxic effect in the studied cell lines, a range of concentrations was tested for each inhibitor. 
 
 
  
 
 
 
(A) (B) 
 (C)  
Figure 3.2 – Representation of the molecular structure of GW4869 (A), fumonisin B1 (B) and myriocin (C).  
 
 
Figure 3.3 – Ceramide biosynthesis pathways and inhibitors: GW4869, fumonisin B1 and myriocin (red). Adapted 
from (Hannun and Luberto, 2000). 
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To test the concentration range of the two inhibitors a solution of GW4869 50 µM and of 
FB1 100 µM were diluted in supplemented medium and used to obtain the solutions with the 
selected concentrations. Cell lines were pre-incubated and co-incubated with each concentration 
of inhibitors (GW4869: 5, 10, 20 and 50 µM; FB1: 1, 5, 10, 15, 20, 40, 60 and 100 µM, for both 
cell lines). The concentration of GW4869 and fumonisin B1 were chosen according to their effect 
on cell’s viability, i.e. the higher concentration that had a lesser toxic outcome was chosen. 
The pre-incubation consists in the medium removal and addition of fresh medium with 
the inhibitors to each well, during 30 minutes for GW4860 and 2 hours for fumonisin B1. Then, 
the medium containing the drugs was replaced by fresh medium for 48h. In the co-incubation, 
medium containing the inhibitor was added to each well during 48h.     
All the optimizations for myriocin (C21H39NO6; Enzo Life Sciences, Figure 3.2) had already 
been done by our research group (Silva, 2012 ; Master thesis). The inhibitor was dissolved in 
DMSO and a stock solution with 25 mM was prepared and stored at -20ºC.     
Following the determination of the adequate concentrations of inhibitors, they were 
tested in combination with sodium acetate (CH3COONa.3H2O; Panreac Quimica SA, Spain), which 
from now on we will refer to as acetate. The concentration of acetate which is lethal to 50% of the 
cells, the half maximal inhibitory concentration (IC50), was determined in 24 and 96-well plates, 
for both cell lines, using the MTT assay. The following concentrations of acetate were tested: 70, 
100, 120, 140 and 200 mM, in 24-well plates, and two additional concentrations, 280 and 400 
mM, in 96-well plates, for HCT-15 cell line; and 50, 70, 110, 140 and 220 mM in 24-well plates 
and 110, 125, 140, 180, 220, 300, 400 mM of acetate were tested in 96-well plates, for RKO 
cell line.  
 
Table I – Concentrations of acetate used in the MTT assays.   
 
 [Acetate] (mM) 
 HCT -15 RKO 
 24-well plate 96-well plate 24-well plate 96-well plate 
IC50 100  206 74  140  
intermediate IC50  150  309  111  210  
2 x IC50 200 412  148  280  
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Once the IC50 values for acetate were established (Table I) cell viability was assessed by 
the MTT assay, in both cell lines, after co-incubation with 5 µM, 10 µM and 150 nM of GW4869, 
fumonisin B1 and myriocin respectively, and with acetate for 48h at concentrations corresponding 
to the IC50, intermediate IC50 or 2 x IC50 values. 
3.4 Statistical analysis 
 The data presented are, at least, from two independent experiments. Data are expressed 
as mean ± SEM or mean ± SD. The results were analyzed using one-way ANOVA, followed by a 
Dunnet’s post test, when comparing the control and treated cells from one cell line. Differences 
were considered statistically significant when p ≤ 0.05. All the analyses were performed using 
GraphPad PRISM software. 
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Changes in intracellular ceramide levels have been linked to modulation of apoptosis in 
mammalian cells. Many inducers of ceramide accumulation are known to induce apoptosis and 
growth suppression and changes in ceramide cellular contents occur prior the execution phase of 
apoptosis (Birbes, El Bawab et al., 2002). It is known that, in cancer cells, apoptosis can be 
triggered by the increase in ceramide levels, using inhibitors of ceramide synthesis or externally 
employing cell-permeable ceramide analogues (Selzner, Bielawska et al., 2001; Siskind, 2005).   
Our goal was therefore to characterize the contribution of enzymes involved in ceramide 
metabolism to apoptotic cell death induced by acetate in CRC cells. For this purpose we used 
different pharmacological inhibitors of specific steps of ceramide metabolism. It was therefore 
necessary to determine, in a first approach, the sub-lethal concentration of the inhibitors (section 
4.1) as well as the half maximum inhibitory concentration of acetate (IC50) (section 4.2) for the 
two CRC cell lines selected (HCT-15 and RKO). The role of ceramide metabolism on loss of cell 
viability induced by acetate was then assessed by determining the effect of ceramide inhibitors at 
the concentrations selected, alone or in combination, on the loss of cell viability induced by 
exposure to the IC50, an intermediate concentration and 2 x IC50 of acetate. 
  
4.1 Optimization of different concentrations of ceramide pathway inhibitors 
in CRC cell lines  
 The first part of the project was to test the ceramide inhibitors, GW4869 and fumonisin 
B1 (FB1), on HCT-15 and RKO cell lines (Figure 4.1 and 4.2), to observe their effect on cellular 
viability and define an adequate concentration of each one to be used later in combination with 
acetate. Several concentrations of GW4869 and FB1, in the micromolar (µM) range, were tested, 
according to what was already previously described in other studies (Luberto, Hassler et al., 
2002; Marchesini, Luberto et al., 2003; Kouadio, Mobio et al., 2005; Cianchi, Cortesini et al., 
2006; Nagata, Partridge et al., 2006). 
The cell lines used in this study were pre-incubated 30 minutes with GW4869 or 2h with 
FB1, or co-incubated with the inhibitors for a period of 48 hours.    
The highest concentration of GW4860 (50 µM), reached a final concentration of 0.25% 
DMSO, higher than the limit normally used of 0.1%, thus it was tested to see an eventual effect of 
DMSO on cellular viability on its own. As it can be seen on Figure 4.1, no significant difference 
was found between treatment with 0.25% of DMSO and untreated cells, on both cells lines. For 
that reason, the conditions tested were compared to untreated cells - negative control (C-).  
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Figure 4.1 – Effect on cellular viability of different concentrations of GW4869 on HCT-15 (A) and RKO (B) cell 
lines, by MTT assay. Cells were seeded at a density of 1x104 cells/well (A) and 7,5x103 cells/well (B), in a 96-well 
cell culture plate. Different concentrations of GW4869 were incubated during 30 min (pre-incubation) and 48h (co-
incubation). Negative control (C-) corresponds to cells incubated with fresh complete medium and the positive 
control (C+) corresponds to cells treated with 500 µM (A) and 1,5 mM (B) of hydrogen peroxide (H2O2), for HCT-15 
and RKO cell lines respectively. The percentage of viability was calculated relatively to the value of absorbance 
obtained for the negative control. For each bar, mean ± SEM for two independent experiments (n=2) is represented. 
* p≤0.05; ** 0.01≤p≤0.001; *** p≤0.0001, compared to control cells (C-), since the DMSO highest dose used 
revealed no significant differences compared to untreated cells (C-).  
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The inhibitor of nSMase (GW4869) seemed to have a similar effect on HCT-15 and RKO 
cell lines, as the percentages of viability are approximately the same. On a general view, the 
viability tended to diminish as the concentration of the drug increased, either in pre or co-
incubation, except on the highest concentration (50 µM), where the percentage of viability slightly 
increased, especially with the RKO cell line.  
 In the pre-incubation, no important changes in cell viability were verified. When cells 
were co-incubated with 20 µM of GW4869, a significant alteration in viability of cells in this 
condition was observed. The cellular viability also decreased when cells were treated with 50 µM 
of GW4869, although the difference was only visible in HCT-15 cells.  
The behaviour of RKO cells pre-incubated with GW4869 (Figure 4.1-B) was similar to that 
observed in HCT-15. In the co-incubation condition, a concentration of 10 µM of GW4869 was 
sufficient to significantly alter the value of viable cells but, when the cell line was treated with a 
concentration of 50 µM of GW4869 the percentage of cellular viability increased again.   
Fumonisin B1, an inhibitor of the ceramide synthase (CerS), had a different impact than 
GW4869, on the cell lines studied (Figure 4.2). 
For the HCT-15 cell line there were no significant alterations of the cellular conditions, 
when cells were pre-incubated with FB1 (Figure 4.2-A). Concerning the co-incubation, a decrease 
on cell viability started to be observed at a concentration of 10 µM of FB1. Thereafter, the 
decrease on cellular viability was proportional to the increase in the concentration until 60 µM of 
FB1.  
The same pattern can be seen on RKO cell line (Figure 4.2-B). There was no main 
alteration on the viability of the cells, regarding the pre-incubation but, on the opposite, the co-
incubation led to a significant loss in RKO cellular viability (when the concentration of this drug 
reached 40 µM), but not as marked as it happened with HCT-15 cells. Like it was observed with 
the inhibitor of nSMase (GW4869), the highest concentration of FB1 tested (100 µM), on both cell 
lines, did not lead to significant changes in cellular viability, either in pre-incubation or co-
incubation. 
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Figure 4.2 – Effect on cellular viability of different concentrations of fumonisin B1 (FB1) on HCT-15 (A) and RKO (B) 
cell lines, by MTT assay. Cells were seeded at a density of 1x104 cells/well (A) and 7,5x103 cells/well (B), in a 96-
well cell culture plate. Different concentrations of FB1 were incubated during 2h (pre-incubation) and 48h (co-
incubation). The negative control (C-) corresponds to cells incubated with fresh complete medium and the positive 
control (C+) corresponds to cells treated with 500 µM (A) and 1,5 mM (B) of hydrogen peroxide (H2O2), for HCT-15 
and RKO cell lines respectively. The percentage of viability was calculated relatively to the value of absorbance 
obtained for the negative control. For each bar, mean ± SEM for three independent experiments (n=3) is 
represented. * p≤0.05; ** 0.01≤p≤0.001; *** p≤0.0001, compared to control cells (C-). 
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4.2 Determination of acetate half maximum inhibitory concentration (IC50) for 
HCT-15 and RKO cell lines 
 The IC50 of acetate was determined on 24 and 96-well cell culture plates, using the MTT 
assay. HCT-15 cells were seeded at a density of 7x104 and 1x104 cells/well in 24 and 96-well cell 
culture plates, respectively. For RKO, cells were seeded at a density of 2,5x104 and 7,5x103 
cells/well in 24 and 96-well cell culture plates, respectively. After the total adherence of the cells, 
acetate treatment was applied, consisting in a wide-ranging set of concentrations tested for both 
type of cell culture plate. At the defined time point, 48h, MTT assay was performed.  
 As expected the results obtained showed that cellular viability decreased with increased 
concentrations of acetate in both cell lines (Figure 4.3). RKO cells seemed to be more vulnerable 
to acetate, as lower concentrations were needed to reach the half maximum inhibitory 
concentration comparing with HCT-15 cell line.    
 Looking at the graph for HCT-15 cells (Figure 4.3-A), it can be visualized that the acetate 
concentrations used with 96-well plate assays were higher than those used in 24-well plate 
assays. The 70 mM concentration tested in 24-well plates was already cytotoxic for HCT-15 cells 
and the other concentrations tested (100, 120, 140 and 200 mM) led to a gradual decrease of 
cell viability. Under these conditions the IC50 of acetate was estimated to be 100 mM in 24-well 
plates. For the 96-well plates we could observe that the first four concentrations tested (70, 100, 
120 and 140 mM) did not alter in a noteworthy way the cellular viability, leading to what could be 
called a “plateau”. When 200 mM of acetate was tested cellular viability dropped significantly, 
becoming very low when cells were treated with higher concentrations. The IC50 determined for 
HCT-15 cells in 96-well plates was 206 mM, approximately twice the concentration obtained in 
24-well plates.  
 The effect of acetate tested in RKO cells (Figure 4.3-B) presented a similar pattern to 
HCT-15 cell line, in both cell culture plates used, and higher concentrations of acetate were also 
needed in 96-well plates. On both type of plates the percentages of cellular viability decreased as 
the concentration of acetate increased, although this decrease seemed to reach lower viability 
more rapidly in 24-well plates. Observing RKO cell line, the first concentrations tested in 24 and 
96-well plates, 50 mM and 110 mM respectively, resulted in a similar decrease of the percentage 
of cellular viability. Analysing the remaining concentrations of acetate tested in both plates, the 
decrease observed in the 24-well plate (corresponding to the concentrations of 70, 110, 140 and 
220 mM) was more abrupt. The acetate IC50 value determined for 24-well plate was 74 mM. 
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Regarding 96-well plates the effect of the remaining concentrations (125, 140, 180, 220, 300 
and 400 mM) resulted in a more gradual decrease in the viability of RKO cells. According to the 
responses obtained for the RKO cell line with the 96-well plates 140 mM of acetate was 
estimated as the IC50 value. 
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Figure 4.3 – Effect of different concentrations of acetate on cellular viability of HCT-15 (A) and RKO (B) cell lines, 
determined by MTT assay. HCT-15 and RKO cellular density was 7x104 and 2,5x104 cells/well, in 24-well plates, and 
1x104 and 7,5x103 cells/well, in 96-well plates, respectively. Acetate (3M) treatment latest 48h before cells were 
analysed by MTT assay to determine the cellular viability. The percentage of viability was calculated relatively to the 
value of absorbance obtained for the negative control (untreated cells). 
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4.3 Effect of ceramide pathway inhibition on acetate-induced cell death in 
CRC cells 
The next step in the project was to evaluate the effect of different inhibitors of specific 
steps of ceramide metabolism, alone or in combination, in the response to acetate in CRC cells. 
It was decided to test both the effect of pre-incubation with the inhibitor followed by the treatment 
with acetate alone, and the effect of the inhibitor along with treatment with acetate (co-
incubation), on the loss of cell viability induced by acetate. We used C2-ceramide as a positive 
control in order to show that these cells were responsive to increased levels of ceramide as 
already previously demonstrated by our group (Silva, 2012 ; Master thesis). 
  
4.3.1 Effect of GW4869 and fumonisin B1 in the acetate response on CRC cell 
lines 
 The effect of GW4869 or FB1 in combination with acetate was evaluated. From now on all 
the assays were performed in 96-well plates, in order to save reagents and material in the 
experimental work. The acetate concentrations used are presented in Table II (in some cases, 
other concentrations different than those listed on Table II, were used to obtain additional 
information).  
 
Table II – Concentrations of acetate used in 96-well cell culture plates for MTT assay.   
 
The cell lines studied were treated with 20 µM of GW4869, during 30 minutes (pre-
incubation treatment) or with 5 µM of GW4869, during 48h (co-incubation treatment). For the 
fumonisin B1 assays, 60 µM were used in pre-incubation conditions and 10 µM in co-incubation 
conditions. In all the conditions tested, acetate was added during 48h and, in the case of co-
incubation, acetate was added to the cells at the same time as the inhibitor.  
 
 
 [Acetate] (mM) 
 HCT -15 RKO 
IC50 206 
309 
412  
140  
210  
280  
intermediate IC50  
2 x IC50 
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Figure 4.4 – Incubation of HCT-15 (A) and RKO (B) cell lines with GW4869 and acetate and determination of 
cellular viability, using MTT assay. HCT-15 and RKO were seeded, in 96-well plates, at a density of 1x104 and 
7,5x103 cells/well, respectively. Pre-incubation represents treatment with 20 µM of GW4869, followed by 48h of 
treatment with acetate. Co-incubation represents treatment with 5 µM of GW4869 and acetate for 48h. Negative 
control (C-) corresponds to cells incubated with fresh complete medium and the positive control (C+) corresponds to 
cells treated with 500 µM (A) and 1,5 mM (B) of hydrogen peroxide (H2O2) and C2-ceramide (35 µM). The 
percentage of viability was calculated relatively to the value of absorbance obtained for the negative control.  For 
each bar, mean ± SEM for two independent experiments (n=2) is represented. * p≤0.05; ** 0.01≤p≤0.001; *** 
p≤0.0001, compared to control cells (C-); ## 0.01≤p≤0.001 for comparison between treatments.  
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Cellular viability assays of both cell lines with the inhibitor of the nSMase (GW4869) and 
acetate, using pre- and co-incubation conditions, showed that the cellular viability values were not 
significantly different, i.e. the inhibitor did not change significantly the effect of acetate on cellular 
viability. In fact, when HCT-15 cells were submitted to pre- or co-incubation conditions either 
small increases or decreases in cellular viability could be observed compared to the control with 
acetate, but none of these alterations were enough marked to really sustain a (protective or 
synergistic) action of GW4869 upon acetate-induced apoptosis (Figure 4.4-A). Concerning the 
RKO cell line equivalent conclusions could be drawn, though a slight increase in cellular viability 
of RKO cell line for co-incubation with acetate 210 and 280 mM was observed, the difference 
was not of statistical significance (Figure 4.4-B).  
The effect of fumonisin B1, inhibitor of the CerS, on acetate induced loss of cellular 
viability of both cell lines was also assessed under pre- and co-incubation conditions (Figure 4.5). 
The results obtained with HCT-15 cells demonstrated that, like GW4869, FB1 caused 
slight alterations in the loss of cellular viability induced by acetate both under pre- or co-
incubation conditions with the inhibitor. Nevertheless, for the IC50 of acetate (206 mM) there was 
a significant difference between the incubation with acetate alone and the pre- and co-incubation 
(treatment with acetate and FB1). This decrease on the cellular viability was not expected 
assuming that ceramide mediates acetate-induced cell death. According to this hypothesis 
inhibition of ceramide metabolism would lead to an increase in cellular viability. However, this 
sensitizing effect of FB1 was no more detected for treatment with the acetate intermediate IC50 
(309 mM) and the 2 x IC50 (412 mM) values.  
Concerning the RKO cell line, a similar behaviour was observed. Indeed a significant 
decrease was observed when cells were treated with 140 mM of acetate (IC50) and co-incubated 
with FB1, compared with cells treated with 140 mM of acetate. This decrease was also detected 
for 2 x IC50 of acetate, under co-incubation conditions but was not statistically significant. 
Taking into account the results obtained it was decided to perform only co-incubation 
assays with the ceramide inhibitors since there was no relevant differences between the results 
obtained for the pre and co-incubation assays. 
 
 
 
 
Chapter 4 - Results 
52 
 
HCT-15  Fumonisin B1 + Acetate
C
- )
2O
2
C
+ 
(H
C
2-
C
er
am
id
e M
60
 
M
10
 
10
0 
m
M
20
6 
m
M
30
9 
m
M
41
2 
m
M
0
20
40
60
80
100
120
Controls
Pre-incubation - 60 M
FB1 (2h)
Co-incubation - 10 M
FB1 (48h)
Acetate
_______________________________
Acetate
***
_______
***
*
 
 
###
##
***
______
***
______
(A)
***
V
ia
b
il
id
a
d
e
 c
e
lu
la
r 
(%
)
 
RKO  Fumonisin B1 + Acetate
C
- )
2O
2
C
+ 
(H
C
2-
C
er
am
id
e M
60
 
M
10
 
75
 m
M
14
0 
m
M
21
0 
m
M
28
0 
m
M
0
20
40
60
80
100
120
Controls
Pre-incubation - 60 M
FB1 (2h)
Co-incubation - 10 M
FB1 (48h)
***
______
Acetate
______________________________
Acetate
***
*
______
***
______
 
##
***
______
(B)
C
e
ll
u
la
r 
V
ia
b
il
it
y 
(%
)
***
 
Figure 4.5 – Incubation of HCT-15 (A) and RKO (B) cell lines with fumonisin B1 and acetate and determination of 
cellular viability, using MTT assay. HCT-15 and RKO were seeded, in 96-well plates, at a density of 1x104 and 
7,5x103 cells/well, respectively. Pre-incubation represents treatment with 60 µM of FB1, followed by 48h of treatment 
with acetate. Co-incubation represents treatment with 10 µM of FB1 and acetate for 48h. Negative control (C-) 
corresponds to cells incubated with fresh complete medium and the positive control (C+) corresponds to cells 
treated with 500 µM (A) and 1,5 mM (B) of hydrogen peroxide (H2O2) and C2-ceramide (35 µM). The percentage of 
viability was calculated relatively to the value of absorbance obtained for the negative control. For each bar, mean ± 
SEM for three independent experiments (n=3) is represented. * p≤0.05; ** 0.01≤p≤0.001; *** p≤0.0001, compared 
to control cells (C-); ## 0.01≤p≤0.001, ### p≤0.0001 for comparison between treatments. 
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4.3.2 Effect of GW4869, fumonisin B1 and myriocin in acetate-induced cell 
death in CRC cells 
 To further explore the inhibition of ceramide biosynthesis pathways and to elucidate if 
acetate really triggers apoptosis via ceramide, it would be necessary to block all the major 
pathways that lead to ceramide generation. Therefore including another inhibitor of the ceramide 
pathways in the experiments seemed to be relevant and these results were previously obtained 
by our research team (Silva, 2012 ; Master thesis).  
Myriocin, a compound that inhibits the action of SPT (serine palmitoyltransferase) was 
included in the experiments to assess the role of the de novo synthesis pathway blockage. The 
concentration of this inhibitor to be used had already been established in a previous work of our 
group and was 150 nM for the two cell lines (Silva, 2012 ; Master thesis). The use of myriocin 
alone or together with GW4869 (5 µM) and FB1 (10 µM) could indicate, in case it causes a 
decrease in the loss of cellular viability induced by acetate, that ceramide is involved in acetate 
induced cell death.  
 Results of the experiments with HCT-15 and RKO cell lines were similar. For the HCT-15 
cell line the combined effect of GW4869, FB1 and myriocin did not lead to an increase in cellular 
viability, comparing with cells treated only with acetate (Figure 4.6-A). Instead all the treatments 
induced a decrease on cellular viability similar to acetate and statistically significant, when 
compared with the negative control. 
The data collected from HCT-15 cells treated with acetate and the three inhibitors of the 
ceramide biosynthesis pathways (Figure 4.6-A) demonstrated that there was no noteworthy 
alteration on cellular viability. This result was particularly noticed when cells were treated with the 
intermediate IC50 (309 mM) and the 2 x IC50 (412 mM) doses that led to a similar loss of cell 
viability. With the IC50 dose of acetate (206 mM), it was more evident that there were no 
important changes in viability between the different conditions tested. When cells were incubated 
with acetate and the three drugs (GW4869, FB1, and myriocin), the percentage of viability was 
lower than cells treated only with acetate, cells treated with acetate and FB1, and cells incubated 
with acetate and a combination of inhibitors (GW4869 + myriocin; FB1 + myriocin). These 
alterations on the viability of HCT-15 cells were not statistically significant and were not sufficient 
to affirm that these changes were due to the inhibition of the ceramide pathways and to associate 
its inhibition to acetate-induced cell death. Moreover, when cells submitted to all the treatments 
Chapter 4 - Results 
54 
 
tested were observed under the microscope (Figure 4.7), it remained difficult to notice any 
pertinent change on the cell number or phenotype. 
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Figure 4.6 – Incubation of HCT-15 (A) and RKO (B) cell lines with GW4869, fumonisin B1, myriocin and acetate 
and determination of cellular viability using MTT assay. HCT-15 and RKO were seeded, in 96-well plates, at a density 
of 1x104 and 7,5x103 cells/well, respectively. Cells were incubated with 5 µM of GW4869, 10 µM of FB1, 150 nM of 
myriocin and acetate for 48h. Negative control (C-) corresponds to cells incubated with fresh complete medium and 
the positive control (C+) corresponds to cells treated C2-ceramide (35 µM). The percentage of viability was 
calculated relatively to the value of absorbance obtained for the negative control. For each bar, mean ± SEM for two 
independent experiments (n=2) is represented. * p≤0.05; ** 0.01≤p≤0.001; *** p≤0.0001, compared to control 
cells (C-). 
Chapter 4 - Results 
55 
 
The RKO cell line displayed the same type of outcome as observed in HCT-15 cell line 
(Figure 4.6-B). There were no statistical significant differences between the treatment with 
acetate alone and treatment with acetate and the inhibitors. When cells were treated with the IC50 
dose (140 mM) of acetate, the incubation with acetate alone led to a loss of cell viability lower 
than that observed for all the other conditions.  
For the incubation of RKO cells with the intermediate IC50 (210 mM) and the 2 x IC50 (280 
mM) acetate doses and with the inhibitors alone or in combination, some treatments led to a no 
statistically significant increase in the percentage of cellular viability when compared with acetate. 
Additionally, the treatment with acetate and the three drugs (GW4869, fumonisin B1 and 
myriocin) revealed no major alterations on cell viability. This result was also observed for cells 
treated with the inhibitors combined in different pairs (GW4869 + fumonisin B1; GW4869 + 
Myriocin; fumonisin B1 + Myriocin). Phase contrast photographs visualization (Figure 4.8), just 
before completing 48h of treatment, revealed subtle differences between treatments, which are 
in accordance with the histograms obtained.  
Gathering and analysing all the data collected, we can conclude that no major alterations 
could be observed concerning cellular viability, on the attempt to revert the effect of acetate in 
inducing cell death, using the compounds (GW4869, fumonisin B1 and myriocin) that interfere 
with the biosynthesis of ceramide and its signalling pathways. In summary, ceramide signalling 
does not seem to be relevant in the cell death induced by acetate in CRC cells.  
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Figure 4.7 – HCT-15 cells, incubated (48h) with acetate and inhibitors of ceramide metabolism (GW4869, 
fumonisin B1 and myriocin), observed under the microscope, on phase contrast (100x).   
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Figure 4.8 – RKO cells, incubated (48h) with acetate and inhibitors of ceramide metabolism (GW4869, fumonisin 
B1 and myriocin) - 48h, observed under the microscope, on phase contrast (100x).  
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5.1 Effect of ceramide pathways inhibitors on acetate-induced cell death  
 Over the years, in the attempt of finding new therapy strategies to use in the prevention 
and treatment of colorectal carcinoma (CRC), some studies reported that bacteria of the genus 
Propionibacterium had the capacity to kill human CRC cells, in vitro, triggering a mechanism 
known as apoptosis or programmed cell death (Jan, Belzacq et al., 2002). A protective role 
played by these bacteria was also found to occur in vivo in mouse models (Lan, Lagadic-
Gossmann et al., 2007; Lan, Bruneau et al., 2008). The protection resides not on the bacteria 
itself, but on short chain fatty acids (SCFAs), such as butyrate, propionate and acetate, which are 
products of the fermentative metabolism of these bacteria. These compounds were found to be, 
at least in part, responsible for killing CRC derived cells lines, namely HT-29 and Caco 2 cell lines 
(Jan, Belzacq et al., 2002). 
Results obtained in the present project confirm that acetate is able to induce cell death in 
two different CRC-derived cell lines HCT-15 and RKO, in accordance with previous findings from 
our group that acetate triggers apoptosis in those CRC-derived cell lines (Marques, Oliveira et al., 
2012 ; submitted). Various markers of apoptosis were found to take place after acetate treatment 
such as DNA fragmentation, phosphatidylserine exposure to the outer leaflet of the plasma 
membrane, caspase activation and the emergence of a sub-G1 cell population (Marques, Oliveira 
et al., 2012 ; submitted).  
The same observation had already been made by Jan research team, which stated that 
SCFAs (namely acetate and propionate) were responsible for inducing apoptotic features in 
colorectal carcinoma cells. Chromatin condensation, nuclei shrinkage and fragmentation, 
activation of caspase 3 and formation of apoptotic bodies were observed. In addition, evidences 
found implicated mitochondria in the process including increased mitochondrial inner membrane 
permeability, ROS accumulation, and involvement of ANT, a putative SCFA target, in the cell 
death mechanism (Jan, Belzacq et al., 2002).  
In S. cerevisiae, acetic acid has proved to induce mitochondria-mediated apoptotic 
process displaying similar characteristics as found in SCFAs-mediated cell death in CRC cells. 
Indeed, ACC carriers (the mitochondrial yeast orthologues of the mammalian adenine nucleotide 
translocator, ANT) are required for mitochondrial outer membrane permeabilization (MOMP), 
cytochrome c release in yeast apoptosis (Pereira, Camougrand et al., 2007) and ANT, a putative 
component of the mammalian PTPC (permeability transition pore complex), was suggested as a 
potential SCFA target (Jan, Belzacq et al., 2002). Moreover, it was found that in both cases the 
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mitochondrial dysfunctions induced by SCFAs, in CRC cells, can also be partially inhibited by 
expression of anti-apoptotic members of the Bcl-2 protein family (Jan, Belzacq et al., 2002; 
Saraiva, Silva et al., 2006). 
 Recently it was found that Pep4p (the yeast orthologue of human cathepsin D) is 
released from the vacuole to the cytosol, in cells undergoing acetic acid-induced apoptosis, and it 
plays a protective role in the active cell death process (Pereira, Chaves et al., 2010). Notably, in 
accordance with this observation our group showed that acetate also triggers LMP (lysosome 
membrane permeabilization) and cathepsin D release to the cytosol in HCT-15 and RKO CRC 
derived cell lines. Moreover, we found that inhibitors of cathepsins (including cathepsin D) 
enhanced acetate-induced apoptosis of CRC cells, suggesting a potential protective role of 
cathepsin D against apoptosis in CRC cells (Marques, Oliveira et al., 2012 ; submitted) similar to 
Pep4p. Indeed deletion of Pep4p conferred a higher susceptibility of yeast to acetic acid-induced 
apoptosis (Pereira, Chaves et al., 2010).  
Besides being not well understood, the relation of cathepsin D with CRC have revealed 
that its expression might be higher in tumour cells (Yilmaz, Uzunlar et al., 2003) as also proved 
in HCT-15 and RKO cells (Marques, Oliveira et al., 2012 ; submitted). Therefore, expression of 
cathepsin D in CRC might be beneficial to its progression and this molecule could be a potential 
target in CRC therapy.     
The results of the present study showed that acetate leads to a significant reduction in 
cellular viability of HCT-15 and RKO CRC derived cell lines, which is in accordance with our group 
and others groups observations. 
On both cell lines studied, the acetate IC50 determinated in 96-well plates was twice the 
IC50 determinated in 24-well plates (Table I and Figure 4.3). This fact might be explained by the 
difference between the size of the well, the cellular distribution and interactions between the cells 
and the culture environment. The 24-wells have higher dimensions, thus the cells are more 
distant from each other, despite a higher number of cells being seeded on these plates and, 
therefore, providing a higher contact between acetate and cells. The interaction of the cells with 
their environment, like gas exchange (O2 and CO2) for example, might influence the response to 
acetate.  
The balance between proliferation and cellular death is a key aspect in tumour 
development and biological active sphingolipids play a major role in the regulation of various 
processes that are involved in cancer pathogenesis (Ogretmen and Hannun, 2004). Ceramide is 
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one of these important lipids which are indispensable in the regulation of mechanisms such as 
cell growth, senescence, cell death, adhesion, migration, inflammation, angiogenesis, and 
intracellular trafficking (Hannun and Obeid, 2008). As a consequence, the major objective of the 
current project was to understand if ceramide is involved in the response to acetate on colorectal 
cancer cell lines. In the attempt of elucidate this particular topic, we aimed to test whether 
interfering with ceramide biosynthetic pathways affects acetate induced cell death. A support to 
this idea is that several chemotherapeutic or chemopreventive agents were reported to lead to 
cell death (mostly through apoptosis), associated with an increase of ceramide endogenous levels 
(Moussavi, Assi et al., 2006; Huang, Chen et al., 2011). Also, a study of human colon cancer 
revealed that the levels of ceramide are 50% lower than those found in normal colon mucosa 
(Selzner, Bielawska et al., 2001), and that application of ceramide analogues and ceramidase 
inhibitors, activates various pro-apoptotic molecules. Thus, it seems to be important to look 
whether the intracellular pool of ceramide is altered during acetate-induced cell death and the 
effect of inhibitors ceramide metabolism on cell survival. 
Three principal inhibitors of the ceramide pathways were used: GW4869, fumonisin B1 
and myriocin. GW4869 is a compound that inhibits the neutral sphingomyelinase (nSMase) that 
is part of the SMase pathway, both in vitro and in vivo (Luberto, Hassler et al., 2002); fumonisin 
B1 is known to act on the salvage and de novo synthesis pathways of ceramide, inhibiting both 
the acylation of sphingosine and dihydrosphingosine by ceramide/dehydroceramide synthase 
(CerS/LASS) (Kitatani, Idkowiak-Baldys et al., 2008); and myriocin is a serine 
palmitoyltransferase  (SPT) inhibitor acting on the de novo synthesis pathway.  
  
5.1.1 Inhibition of the sphingomyelinase pathway: effect of GW4869 on 
cellular viability of CRC cell lines 
 The experiments with GW4869 and acetate (Figure 4.4 and 4.6) did not show an 
increase in cell viability when cells were co-treated with these two compounds. Our results 
showed that inhibition of the SMase pathway did not revert, in a significant manner, the loss of 
viability caused by acetate alone, on both cells lines studied. Neither the pre-incubation or co-
incubation condition made a difference on the results observed (Figure 4.4). Such observation 
could be a consequence of the existence of alternative pathways, for ceramide synthesis, that 
would compensate this inhibition. It is also known that three mammalian forms of nSMases 
exists (nSMases 1-3) and they play important roles in signalling processes (Figure 5.1). Several 
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cellular stresses, represented in Figure 5.1, have been shown to activate nSMases, including 
various members of the tumour necrosis factor (TNF) receptor family, and anticancer drugs 
(Chatterjee, 1999; Krönke, 1999; Levade and Jaffrézou, 1999). 
 
Figure 5.1 – Signalling roles of neutral sphingomyelinases in response to potential activators. Adapted from (Wu, 
Clarke et al., 2010).  
The nSMase 2 is located in the plasma membrane of cells, and GW4869 was recognized 
as a nSMase 2 inhibitor, both in vitro and in vivo (Wu, Clarke et al., 2010). This enzyme seems to 
be implicated in cell growth as a study employing MCF7 (breast cancer) cell line, overexpressing 
nSMase2 in cells, showed a 40% diminution in the sphingomyelin levels and accelerated 
sphingomyelin catabolism, leading to an increase of 60±15 % of ceramide levels in nSMase2-
overexpressing cells (Marchesini, Luberto et al., 2003). The stable overexpression of nSMase2 
led to a (30-40%) decrease in the growth rate at the late exponential phase.  
A study by Luberto and colleagues, in 2002, demonstrated that GW4869 protected, in a 
dose-dependent manner, MCF7 cells from TNF-induced apoptosis, acting also in the inhibition of 
cytochrome c release from mitochondria and caspase 9 activation (Luberto, Hassler et al., 
2002). In this study, cells were pre-treated for 30 min with either 10 or 20 µM of GW4869, 
followed by a TNF treatment for 24h. Maybe if we had tested, in the present project, different 
time points besides 48h, we could have obtained different results, exhibiting the protective effect 
verified by Luberto.  
Furthermore, GW4869 inhibitor failed to block the novel histone deacetylase inhibitor 
LAQ824-mediated apoptosis in leukaemia cells (U937) (Rosato, Maggio et al., 2006). These 
results suggest that acetate-induced cell death might not be directly linked to ceramide synthesis 
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by nSMase, at least in HCT-15 and RKO cell lines, as observed in the present study. 
Determination of nSMase activity before and after treatment with acetate would allow supporting 
this interpretation. 
  
5.1.2 Inhibition of de salvage and de novo synthesis pathways: effect of 
fumonisin B1 on cellular viability of CRC cell lines 
 The effect of fumonisin B1, an inhibitor of the ceramide synthase (CerS) that acts on the 
salvage and de novo pathways of ceramide, on acetate-induced apoptosis in HCT-15 and RKO 
cell lines, was also tested. As seen on Figure 4.5 and 4.6, the expected increase in the 
percentage of viable cells when treated with the inhibitor and acetate, did not occur. Rather a 
significant decrease in cell viability was observed in HCT-15 and RKO cell lines after pre- and co-
incubation with 206mM of acetate and after co-incubation with 140 mM of acetate, respectively 
(Figure 4.5). 
Fumonisins have been extensively employed to understand the function of ceramides 
and other sphingolipids in cultures of mammalian cell lines. Somewhat in a paradoxal way, a 
certain number of studies use fumonisins to induce apoptosis and, in other contexts, these 
compounds are growth stimulatory and anti-apoptotic rather than cytotoxic (Desai, Sullards et al., 
2002).  
Studies have previously demonstrated that, in anticancer drug mediated apoptosis 
scenarios, such as of daunorubicin-induced apoptosis in leukaemia cells - P388 and U937 cell 
lines, FB1 was able to block the elevation of ceramide levels and apoptosis (Bose, Verheij et al., 
1995). In colorectal cancer models, previous experiments showed that when FB1 (10 µM) was 
used with a chemotherapeutic agent – Irinotecan – CRC cell death diminished significantly and 
increased in 95% cell viability (Litvak, Bilchik et al., 2003). The increase in sphingosine-1-
phosphate is likely to be a considering factor in cells where fumonisins are growth stimulatory 
instead of toxic and could play a major role in apoptosis inhibition. On the other hand, when FB1 
is added to cells in culture, it causes elevations in sphinganine (due to the inhibition of de novo 
pathway), and results most of the times in growth arrest (Ciacci-Zanella, Merrill Jr et al., 1998) 
and apoptosis (Schmelz, Dombrink-Kurtzman et al., 1998). This could be one of the reasons 
behind the decrease in the percentage of viability in HCT-15 and RKO cells submitted to FB1 and 
acetate treatment.   
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The inhibition by FB1 may result in the increase of free sphingoid bases and their 1-
phosphates and decreased ceramide biosynthesis. The inhibition of ceramide synthase can 
inhibit cell death (ceramide-induced), but promote free sphingoid base-induced cell death. It is 
the balance between the change in anti- and pro-apoptotic sphingolipid species (e.g. decreased 
ceramide and increased sphingosine-1-phosphate levels or increased ceramide, free sphingoid 
bases and altered fatty acids levels) that will determine the cellular response - Figure 5.2 (Riley, 
Enongene et al., 2001). Hypothetically in the present study, the inhibition by FB1 may cause an 
elevation of sphingosine levels, which has pro-apoptotic effect, as represented in the sphingolipid 
rheostat, thus justifying the fact that there is a decrease in cell survival in both cell lines. 
 
 
Figure 5.2 – Schematic representation of the sphingolipid rheostat. Ceramide (and sphingosine) favour a block in 
cell proliferation and apoptosis while sphingosine-1-phosphate (S1P) favours proliferation and cell survival. Thus 
sphingosine kinase (SphK) is in an important position to favour cell survival. SPP, sphingosine-1-phosphate 
phosphatase; Cer-synthase, ceramide synthase. Adapted from (Van Brocklyn and Williams, 2012). 
 
It is also important to refer that HCT-15 and RKO cells have different sphingosine kinase 
(SphK) activities. RKO has a much higher activity of both SphK1 (57.90 ± 11.5 pmol/min/mg 
protein) and SphK2 (68.81 ± 11.05 pmol/min/mg protein) than HCT-15 (8.38 ± 1.05 and 4.82 
± 1.34 pmol/min/mg protein, respectively) (Nemoto, Nakamura et al., 2009). Although SphK1 
and SphK2 are closely related, use the same substrate, sphingosine, and generate the same 
product, S1P, they seem to have contrary roles in cells. While SphK1 has a pro-survival role, 
SphK2 is associated with cell growth inhibition and apoptosis (Maceyka, Sankala et al., 2005). A 
probable explanation to these contrasting functions, given by Maceyka and collaborators, is the 
fact that the two proteins are located or translocated to different parts of the cell, and that the 
localized production of S1P has distinct functions; also SphK2 might act in concert with S1P 
phosphatase to convert S1P into sphingosine and then ceramide.  
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These differences in enzyme activity, between the two cell lines, may explain the different 
behaviours observed justifying, for instance, HCT-15 being more prone to survival. Generally, 
when treated with acetate, HCT-15 is more resistant to acetate than RKO, because higher doses 
of acetate are necessary to diminish the cellular viability of HCT-15 cells in 50%. The higher 
activity of SphK1/2 found in RKO cells might play a decisive role in the response to this inhibitor, 
explaining in part the results obtained. Furthermore, the levels of SphK2 (pro-apoptotic) are 
slightly higher than SphK1 (pro-survival) in RKO, in opposition to HCT-15, which may explain why 
a higher dose of acetate is needed to induce cell death in HCT-15. 
      
5.1.3 Inhibition of the de novo synthesis pathway: effect of myriocin on 
cellular viability of CRC cell lines 
 Myriocin, as described before is an SPT inhibitor acting on the generation of ceramide by 
the de novo pathway. This compound inhibits both mammal and fungal SPT in cell free 
preparations and its IC50 values are included in the nanomolar (nM) range (Miyake, Kozutsumi et 
al., 1995; Hanada, 2003). 
 From the results obtained by our research group (Silva, 2012 ; Master thesis) and in 
order to observe the influence of the de novo synthesis pathway in acetate-induced cell death in 
HCT-15 and RKO cell lines, 150 nM of myriocin were used in each experiment (Figure 4.6) in co-
incubation with acetate, for 48h. As observed, there are no meaningful changes in the cellular 
viability of both HCT-15 and RKO cell lines after the treatment of acetate in combination with this 
inhibitor, revealing that this pathway may not be directly involved in acetate signalling cell death. 
These results are in accordance with the ones previously obtained by our research team (Silva, 
2012 ; Master thesis). 
The hindrance of the de novo sphingolipid pathway, alone, did not reverse the effect of 
acetate on the cell lines studied. The generation of ceramide through other pathways may be 
considered, as they could compensate the action of myriocin. Nonetheless, when using this 
compound, we have to have in mind the fact that it is reported that when used for several hours 
it may impede all sphingolipid synthesis and, also, the synthesis of complex sphingolipids 
(Kitatani, Idkowiak-Baldys et al., 2008). 
On the other hand, myriocin has been found to induce growth inhibition, in melanoma 
cells (Lee, Choi et al., 2001), reducing the levels of ceramide, sphingomyelin, sphingosine and 
sphingosine-1-phosphate. Myriocin has also been shown to play a central role in ceramide levels 
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regulation and partially reverting curcumin’s apoptosis-inducing death in colon cancer cell lines 
(Moussavi, Assi et al., 2006). In this study, Moussavi and collaborators reported that the 
induction of apoptosis by curcumin is accompanied with intense ceramide generation, which 
could be attenuated by pre-incubation with myriocin and, also, that cell death could in part be 
reversed by this inhibitor. Therefore, it was important to observe the effect of myriocin in the 
conditions used in the present study, because acetate-induced cell death could lead to a 
comparable outcome (reversion of the viability loss, in the present case) if the de novo ceramide 
synthesis is signalling the process of cell death.  
 
5.1.4 Effect of inhibiting different ceramide pathways on the cellular viability 
of HCT-15 and RKO cell lines 
 To further explore the role of ceramide biosynthesis involvement in acetate-induced cell 
death, in CRC cell lines, different inhibitors of ceramide pathways were used simultaneously, in 
different combinations (Figure 4.6).  
 To begin with, GW4869 and fumonisin B1 were incubated together with acetate, as those 
two compounds would allow blocking the principal pathways of ceramide synthesis i.e. the 
SMase pathway and the salvage and the de novo pathways. As seen in Figure 4.6, the 
conjugated incubation tested did not alter in a significant manner the percentages of viability, 
neither in HCT-15 nor in RKO cells, comparing to the acetate effect alone. These inhibitors were 
also incubated separately with myriocin, thus inhibiting simultaneously the de novo pathway and 
the SMase pathway (when incubated with GW4869) or inhibiting the de novo pathway at two 
different stages (when incubated with fumonisin B1). These different combinations of inhibitors 
did not result in a significant alteration of the cellular viability on both cell lines - Figure 4.6, 
though a slight increase (not statistically different) in cellular viability was observed when HCT-15 
cells were treated with 206 mM of acetate.   
Having this result in mind, a last combination of inhibitors with acetate was tried: 
GW4869, FB1 and myriocin were incubated all together with acetate, during 48h. With this last 
combination all the pathways above are inhibited and the blockage of the de novo pathway is 
reinforced. Nevertheless, the outcome was the same, although there was a tendency to induce 
an increase in the values of viability, it was not statistically significant, as it would be expected if 
ceramide signalling was relevant in acetate-induced cell death. Consequently, the sphingolipid 
metabolism and ceramide signalling do not appear to be involved in acetate-induced cell death.  
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Small alterations on the level of some sphingolipid species would trigger different cell 
responses as already described. Recently, it has been found that sphingolipid metabolism is 
important in mitochondria-mediated yeast apoptosis induced by acetic acid. The deletion of ISC1, 
orthologue of mammalian nSMase2, or of LAG1, orthologue of mammalian CerS/LASS1 
(longevity assurance gene) improved the survival of yeast cells exposed to acetic acid (Rego, 
Costa et al., 2012 ; accepted). Very often, the processes that occur in the yeast model are very 
similar to those happening in mammalian cells. Therefore, it would be fundamental to carry 
some additional experiments (the quantification of ceramide levels or tracing the ceramide 
metabolism, for instance) as approached in the next chapter, to fully exclude the involvement of 
ceramide in cell death mediated by acetate.  
The effect of desipramine, another inhibitor of the sphingolipid metabolism, which was 
tested on HCT-15 and RKO cell lines in a previous work developed by our group, could also have 
been used. This compound is a tricyclic anti-depressant, which is known to specifically inhibit the 
acid sphingomyelinase (aSMase) in the SMase pathway of ceramide production (Kölzer, Werth et 
al., 2004) and the acid ceramidase (Elojeimy, Holman et al., 2006). The reason why we opted 
not to use it again on the present project is because of the toxicity demonstrated in which the 
acetate effect was accentuated (Silva, 2012 ; Master thesis). These findings were in accordance 
with what had been described about its cytotoxicity and its role in CRC apoptosis (Arimochi and 
Morita, 2006; Arimochi and Morita, 2008). On the other hand, this inhibitor might be very 
interesting as a potential CRC therapy drug, since its action increases the toxicity of certain 
chemotherapeutic drugs (Kabolizadeh, Engelmann et al., 2012), and because it targets ceramide 
metabolism which is frequently deregulated in cancer (Ryland, Fox et al., 2011). 
The alteration of certain parameters in the experiments tested throughout the present 
project could perhaps result in different outcomes. For example, testing different times points 
such as 16, 24 and 32h, instead of only 48h, where cell survival might be too reduced to allow 
the observation of the effect of the different inhibitors tested. Furthermore, it would be useful to 
determine if the inhibitors used changed the intracellular ceramide levels, since it would permit 
the verification of their impact in sphingolipid metabolism on colorectal carcinoma derived cell 
lines.       
Numerous studies demonstrated that increasing the cellular content of ceramide would 
lead to programmed cell death; others have shown that lower cellular ceramide levels interfere 
with apoptosis induced by other agents (Kolesnick and Kronke, 1998; Birbes, El Bawab et al., 
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2002; Siskind, 2005). Moreover, previous studies performed by our research team indicate that 
treatment of HCT-15 and RKO cell lines with extrinsic ceramide (C2-ceramide) induced apoptosis 
on both cell lines, though RKO was more susceptible (Silva, 2012 ; Master thesis). These 
evidences are the consequence of two facets of ceramide: its metabolic conversion into 
sphingosine-1-phosphate or glucosphingolipids, which lead to cellular proliferation, or ceramide 
by itself that generates apoptosis (Huwiler and Zangemeister-Wittke, 2007). The balance between 
proliferation and cell death might be absent in cancer cells and if this balance (cellular 
homeostasis) is successfully restored it could constitute a putative therapy target against tumour 
development (Huwiler and Zangemeister-Wittke, 2007; Huang, Chen et al., 2011).            
 It would be necessary to perform more experiments, for instance, to measure the 
quantities of ceramide present in the cells after the several treatments with inhibitors and acetate 
alone or in combination, in order to draw more reliable conclusions. It is important to have in 
mind that the distinct metabolic capacities of the cell lines (HCT-15 and RKO) and the exposure 
to different compounds, such as GW4869, FB1 and myriocin (interfering in the ceramide 
production) could lead to distinct outcomes. Though, both cells lines ultimately behaved in the 
same way, the fact they have different genetic backgrounds and the intervention with several 
compounds in such a complex sphingolipid metabolism could have end up with different results. 
These facts could partially explain some of apparently contradictory results found in the literature, 
where in some cases using inhibitors of ceramide pathways reverse the effect of a given 
compound that induces cell death or, as it is presented in this project, no reversion is observed. 
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6.1 Final conclusion  
The major goal of the project was to investigate the role of ceramide in acetate-induced 
apoptosis. In order to accomplish this objective we used two colorectal carcinoma cell lines, and 
treated them with three inhibitors of ceramide pathways: GW4869 (inhibitor of the 
sphingomyelinase pathway), fumonisin B1 (inhibitor of the de novo and salvage pathways) and 
myriocin (inhibitor of the de novo pathway), to interfere with the ceramide biosynthesis.  
Inhibitors were tested alone or in combination and in conjugation with acetate. The 
results achieved in the present work indicate that ceramide does not mediate acetate-induced cell 
death in HCT-15 and RKO cell lines. Different inhibitors of sphingolipid metabolism used alone or 
in combination did not reverse the effect of acetate on the decrease of cellular viability of both 
cell lines. In other words, the expected increase of viable cells with the inhibition of ceramide 
pathways was not observed. Therefore, our results suggest that none of the major pathways 
responsible for ceramide production namely the de novo pathway, the salvage pathway and the 
SMase pathway, seems to interfere in the acetate-induced cell death in CRC cells.  
 
6.2 Future perspectives 
Further exploitation of these results would be important to solidify the knowledge 
acquired within this project. The next step could be the evaluation of ceramide levels in the CRC 
cell lines tested before and after the different treatments, as it would give us an idea if changes in 
ceramide amount occur when incubated with acetate alone or acetate and inhibitors of ceramide 
biosynthesis pathways. An example of a technique that could be used to quantify the levels of 
ceramide could be the use of an anti-ceramide antibody (Grassmé, Jekle et al., 2001; Cianchi, 
Cortesini et al., 2006) that allows the relative quantification of ceramide, using fluorescence-
activated cell sorting (FACS). The diacylglycerol kinase (DGK) assay (Bielawska, Perry et al., 
2001; Takahashi, Inanami et al., 2006) is another way to measure the endogenous levels of 
ceramide that could also be used, but more difficult to implement as part of the method consists 
in a thin layer chromatography (TLC).  
Another point that would be interesting to consider in the continuation of the project is 
the efficiency of the inhibition of the ceramide synthesis through the different pathways by the 
inhibitor concentration used. A measurement of the activity of the key enzymes in ceramide 
generation could be assessed, in the presence or absence of the inhibitors as described, for 
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instance, by Takeda and collaborators (Takeda, Tashima et al., 1999). It would give us answers 
about the level of inhibition of the principal ceramide generation pathways. However to apply 
such activity assays it would be necessary to lyse cells to obtain the enzymes, and use 
radioactive substrates to monitor the enzyme reaction with a scintillation counter. The protein 
concentration could be measured using a normal protein assay kit (Takeda, Tashima et al., 
1999).      
Trace ceramide metabolism would also provide interesting complementary information, 
as it would help to confirm if and how acetate triggers ceramide synthesis. To achieve that, 
ceramide synthesis would be followed using radioactive compounds that would enter the 
sphingolipid metabolism (Luberto, Hassler et al., 2002; Litvak, Bilchik et al., 2003). Briefly, the 
method would consist in the addition of a radioactive substrate (the first in the pathway which 
would be studied) to the culture medium (inhibitors could also be added right after, depending on 
the conditions wanted). After that cells would be collected and lipids extracted using the Bligh 
and Dryer method (Bligh and Dyer, 1959), for example. The resultant organic phase would be 
used for ceramide determination, obtained through TLC, used for separation of extracted lipids. 
The ceramide band formed would be recognized by comparison with a standard and radioactivity 
measured using a scintillation counter (Luberto, Hassler et al., 2002).  
  To summarize, our results demonstrated that ceramide synthesis pathways do not 
appear to be involved in the mechanisms related to acetate-induced cell death. Viability assays 
performed are not sufficient on their own to indisputably confirm such suppositions, but they 
certainly are an indicator to take into consideration. In this perspective, complementing studies 
have been made by our research group indicating that acetate stops proliferation and triggers 
apoptosis on its own (using different assays: BrDU incorporation, sulforhodamine B (SRB), 
TUNEL, caspase 3 activity, AnnexinV/PI staining) and it is responsible for lysosomal membrane 
permeabilization (LMP), and cathepsin D release into the cytosol (Marques, Oliveira et al., 2012 ; 
submitted).  
Continuation of the investigation would help in the quest to find more reliable answers 
and explanations about the mechanisms hiding behind the role of ceramide in acetate-induced 
cell death.  
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